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 Abstract 
__________________________________________________ 
 
The metabolic syndrome is highly prevalent in western society, and the numbers affected by 
obesity and diabetes continue to rise. This thesis reviews the mechanisms at play and the gaps in the 
literature that, if filled, may increase knowledge of treatment regimes for affected individuals. 
Experimentally, it was demonstrated that the oral glucose tolerance test can be a reliable tool to 
measure insulin sensitivity following adequate dietary and exercise control. Acute and chronic 
cinnamon ingestion was shown to improve insulin sensitivity. Feeding frequency was found to alter 
insulin and ghrelin responses and relationships following mixed-meal ingestion. And finally, 
postprandial lipaemia was found to be attenuated for up to 24 hours following moderate-intensity 
exercise, illustrating the requirement of daily exercise. In summary, oral glucose tolerance tests are 
suitable for experimental interventions; and the clinical management of factors associated with the 
metabolic syndrome should perhaps consider dietary supplements, meal frequency, and exercise 
timing in addition to the traditional dietary and physical activity guidelines currently in practice. 
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1. General Introduction 
___________________________________________________________________________ 
 
 
1.1 The escalating problem of metabolic diseases 
 
Recent long-term epidemiological evidence shows an increase in the prevalence of obesity [1,2]. 
Increasing obesity is a growing concern in western developed nations, and currently, according to a 
Department of Health survey, 65.5% of the population in the UK are overweight (body mass index 
(BMI) > 25 kg.m-2), and 25.4% are obese (BMI > 30 kg.m-2) (Figure 1.1) [2]. These figures have 
escalated in the last 10 years with a 20.5% increase in the number of overweight individuals, and a 
53.6% rise in obesity (Figure 1.1) [2]. Alarmingly, in the UK 18.3% of children aged under 16 years 
old are obese, the proportion has risen by 59.8% over a 10 year period [2]. 
Figure 1.1 – Trends in body mass in the UK 
Panel (i) shows body mass in 2004 across an adult age range. Panel (ii) shows changes in body 
mass from 1993 to 2004. Each bar represents the whole population. Body mass is divided into BMI 
brackets: obese (> 30 kg.m-2), overweight (25-30 kg.m-2), ideal weight (20-25 kg.m-2), underweight (< 
20 kg.m-2). Data adapted from Health Survey for England 2004, Department of Health [2]. 
 
Obesity is an independent risk factor for type 2 diabetes mellitus (T2DM) and symptoms 
associated with the metabolic syndrome [1,3,4]. Excess body fat, particularly abdominal visceral fat, 
leads to impaired glucose and lipid metabolism, causing insulin resistance and hyperinsulinaemia [5]. 
Insulin resistance is a pathological state whereby target tissues are unable to respond to normal 
circulating concentrations of insulin [5]. This is largely determined by environmental factors, such as 
dietary intake and physical inactivity [6], yet genetic predisposition is also well documented in 
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offspring studies [7,8]. In the extreme, these environmental factors, lead to insulin resistance plus 
pancreatic β-cell dysfunction causing T2DM, a state of metabolic disease characterised by 
hyperglycaemia and glucosuria [5,9]. Diabetes is diagnosed with the use of fasting plasma glucose 
(FPG) and postprandial glucose concentrations following an oral glucose tolerance test (OGTT) (see 
Table 1.1), haemoglobin A1c (HbA1c) levels and clinical judgement.  
 
Table 1.1 – Diabetes diagnostic criteria 
Values represent venous plasma glucose concentrations in a non-gestational population. FPG = 
fasting plasma glucose. 2h-PG = plasma glucose concentration 2 h following a 75 g OGTT. * = ADA 
recently considered lowering to 5.6 mmol.l-1. Data adapted from Alberti et al (1998) Diabet Med 15: 
539-553 [10]. 
 
 
Detection of diabetes using the OGTT has been shown to improve long-term health outcome 
and reduce mortality following appropriate treatment [11-13]. If left untreated T2DM patients can 
develop a number of irreversible problems such as renal dysfunction, retinopathy, nephropathy, 
neuropathy, pregnancy complications and vascular dysfunction [14]. Ultimately this increases the risk 
of cardiovascular complications as demonstrated by several longitudinal epidemiological studies, such 
as the UK Prospective Diabetes Study, the San Antonio Heart Study, and the Framingham Offspring 
Study [15-17]. McCarty et al (1994) estimates that approximately 80-90% of diabetes is T2DM, and 
currently in the UK the prevalence of diabetes stands at 4.2% (Figure 1.2), thus there are 
approximately 2.1 million T2DM patients in Britain [2,18,19]. The number affected has increased by 
75% in the past 10 years [2], and it has also been estimated that by the year 2020, approximately 250 
million people worldwide shall be affected by T2DM [20]. In addition, approximately 5% of the 
Plasma Glucose Concentration 
(mmol.l-1)
FPG 2h-PG
Normal < 6.1* < 7.8
Impaired Fasting Glycaemia
OR 
Impaired Glucose Tolerance
Diabetes mellitus > 7.0 > 11.0
6.1 - 7.0 > 7.8
Glycaemic Control
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National Health Service’s budget (c. £3.8 billion per year) is spent on treating and managing diabetes 
in the UK [21]. 
 
Figure 1.2 – Prevalence of diabetes in the UK 
Graph shows increasing prevalence of diabetes in adults with time since 1994. Data adapted 
from Health Survey for England 2004, Department of Health [2]. 
 
 
Insulin resistance is also implicated in a multi-factorial disease known as the metabolic 
syndrome. The metabolic syndrome, originally described by Reaven in 1988, describes a clustering of 
several risk factors for cardiovascular disease (CVD): abdominal obesity, dyslipidaemia (elevated low-
density lipoprotein cholesterol (LDL-c), small dense LDL particles, reduced high-density lipoprotein 
cholesterol (HDL-c), and elevated triglyceride concentrations), impaired glucose tolerance (IGT), and 
hypertension [3]. Several diagnostic criteria for the metabolic syndrome are available (Table 1.2), 
those of the World Health Organisation (WHO), the International Diabetes Federation (IDF) and the 
National Cholesterol Education Program (NCEP) are the most widespread [10,22,23], and whilst 
discrepancies in their sensitivity are documented [24], they do provide a useful tool to detect and 
therefore treat “at risk” individuals. Approximately 25% of the population in the UK are affected with 
the metabolic syndrome, and those affected have a fivefold greater risk of developing T2DM and are 
three times more likely to suffer vascular complications [25-27]. 
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Table 1.2 –Diagnostic criteria for the metabolic syndrome [10,22,23] 
WHO = World Health Organisation. NCEP ATP III = National Cholesterol Education Program 
Adult Treatment Panel. IDF = International Diabetes Federation. IGT = impaired glucose tolerance. 
IFG = impaired fasting glycaemia. † = indicated by T2DM or IFG. * = ADA recently suggested 
lowering this to 100 mg.dl-1 (5.6 mmol.l-1). # = by waist circumference. Adapted from Deen (2004) 
Am Fam Physician 69: 2875-82 [28]. 
 
 
 
As suggested above, diabetes and the metabolic syndrome, conditions underpinned by insulin 
resistance, both predispose to increased risk of CVD. Epidemiological data illustrates that people with 
diabetes are 2-3 times more likely to die of CVD [29-31]. The prevalence of CVD increases with age, 
reflecting age-related changes in body mass and diabetes [2]. Currently in the UK, CVD affects 7.7% 
of the population, and the number of affected individuals has risen by 25.2% in the last 10 years 
(Figure 1.3) [2]. CVD is also the leading cause of all-cause mortality and accounts for approximately 
36% of deaths annually in the UK [32,33]. In addition, in 2004 CVD cost the NHS £16 billion, further 
illustrating the large socio-economic impact of metabolic abnormalities in the UK [34].  
Figure 1.3 – Prevalence of CVD in UK 
Graph shows increased CVD prevalence in adults with time since 1994. Data adapted from 
Health Survey for England 2004, Department of Health [2]. 
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This brief introduction illustrates the escalating problem with metabolic and cardiovascular-
related diseases in the UK, and their association with insulin resistance. As will be discussed later in 
this chapter, lifestyle habits can largely influence such states, and be used to help reduce disease risk. 
The metabolic syndrome, obesity and T2DM each increase one’s risk of developing CVD and dying 
from its complications. Obesity-induced insulin resistance is the underlying pathology and therefore 
understanding its onset will aid in the development of interventions to reduce the risk of CVD-related 
morbidity and mortality. 
 
1.2 Adiposity and insulin resistance 
There is much evidence that implicates increased adiposity with diabetes risk and vascular 
complications (introduced in Section 1.1), showing a strong relationship between excess body-fat and 
insulin resistance [35-37]. Aging contributes to these metabolic abnormalities, but obesity accelerates 
their onset [6]. Obesity results from a long-term positive energy balance; energy intake (diet) 
outweighing energy expenditure (physical activity). Chakravarthy and Booth (2004) stated that the 
hunter-gatherer lifestyle of our ancestors involved large amounts of physical activity, but such habits 
are not routine anymore [38]. Recently, technological advances and transportation have led to food 
abundance and minimal requirement for physical activity. Current statistics show that only 29% of 
adults in the UK achieve minimum exercise guidelines (30 mins on at least 3 days a week), a statistic 
that decreases with age and has been in decline over the last 30 years [39,40]. However, whilst high 
saturated fat and high refined sugar diets are related to the onset of insulin resistance and increased 
risk of T2DM [41-47], British Heart Foundation data show that fat, sugar and total caloric ingestion 
has actually reduced in the UK in the last 30 years [40,48]. Therefore, it is probable that sedentary 
lifestyles are causing energy intake to outweigh energy expenditure, leading to a positive energy 
balance, explaining the increasing trends in obesity in today’s society [49]. 
 
1.2.1 The role of adipose tissue 
  
Adipose tissue plays an important role in lipid metabolism by controlling non-esterified fatty 
acid (NEFA) flux to other peripheral tissues, and by allowing triglyceride hydrolysis and clearance 
 6
from the systemic circulation, acting as a buffer to daily lipid flux [50]. In addition, adipocytes also 
release a number of chemicals and hormones (termed “adipocytokines”) that have actions on skeletal 
muscle, immune cells, neural circuits in the hypothalamus, and other tissues [51,52]. Adipocytokines 
and FFAs are well documented to have direct effects on insulin signalling and insulin action in 
muscle, liver and the endothelium [51-53]. Thus, adiposity must be controlled to maintain adequate 
function and optimum health. 
 
Adipocytes express hormone sensitive lipase (HSL), and lipoprotein lipase (LPL) is found on 
the endothelial lining of the adipose tissue capillary bed [54,55]. These two enzymes are responsive to 
hormonal stimulation. Catecholamines upregulate HSL activity, increasing lipolysis, and therefore 
FFA release into the systemic circulation [54,56], whereas insulin suppresses HSL activity and 
upregulates LPL activity in adipose tissue in the postprandial period to allow increased triglyceride 
clearance from the blood [55,56]. Insulin sensitivity of these enzymes is particularly important to 
maintaining optimal adipose tissue lipid-buffering capacity [50]. With regards to insulin resistance, the 
site of adiposity is also important. Increased abdominal (android) adiposity appears to be more related 
to CVD-risk factors than gluteal or femoral (gynoid) adiposity [57-60]. Furthermore, visceral fat has 
been demonstrated to be more responsive to lipolytic stimuli and less insulin sensitive than 
subcutaneous fat [61-64], a finding that is particularly important to hepatic insulin resistance as 
visceral outflow drains directly into the portal vein, thus FFA output from visceral adipose primarily 
targets the liver [65]. The importance of body fat distribution is exemplified by Klein et al (2004), 
who demonstrated that removing up to 44% of subcutaneous abdominal adipose tissue fails to improve 
any indices of insulin sensitivity (peripheral or hepatic), markers of CVD-risk, or adipocytokine levels 
in obese individuals [66]. 
 
1.2.2 Insulin action 
 
Insulin exerts numerous actions on a variety of cell types, yet the control of glucose homeostasis 
is its major function [67]. The most abundant insulin-responsive tissue in mammals is skeletal muscle, 
which is central to regulation of systemic glucose levels in the postprandial period. Insulin binds to the 
extracellular domain of the insulin receptor (IR) causing autophosphorylation of specific tyrosine 
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residues allowing tyrosine kinase activation and phosphorylation of the intracellular insulin receptor 
substrates (IRS) [67,68]. The IRSs upregulate the phosphoinositol triphosphate pathway by 
phosphorylating phosphoinositol-3-kinase (PI3K), the key enzyme in the insulin signalling pathway 
[67,69]. Activation of PI3K propagates a signal to a number of other intracellular kinases (e.g. protein 
kinase B (PKB/Akt) and protein kinase C (PKC)) that ultimately regulate several cellular functions. 
These functions include glucose transporter-4 (GLUT-4) translocation from intracellular vesicles to 
the cell surface membrane, glycogen synthesis, various elongation and initiation factors involved in 
protein synthesis, various gluconeogenic enzymes involved in hepatic glucose output, enzymes 
involved in fatty acid synthesis and lipolysis, and other effects on gene expression and transcription 
[67-69]. In addition, IRS activation has been demonstrated to regulate the mitogen-activated protein 
kinase (MAPK) pathway involved in cell growth and differentiation and further gene transcription 
[70,71]. Insulin also has actions in adipose tissue, upregulating LPL activity and suppressing HSL as 
described above [65]. In the myocardium, insulin regulates development, fuel substrate utilisation, 
glucose uptake and glycogen synthesis, and cardiac contractility [72-75]. In addition, insulin has an 
important function in the endothelium upon nitric oxide synthase (eNOS), an enzyme that produces 
nitric oxide (NO), a freely diffusible compound that plays a key role in smooth muscle relaxation and 
thus vasodilatation [76,77]. Therefore, postprandially, insulin serves to increase capillary perfusion, 
allowing increased nutrient and hormonal availability to the tissue bed, it upregulates glucose uptake 
and glycogen synthesis, promotes protein synthesis and cell growth, suppresses glycogenolysis and 
glucose output from the liver, and increases adipocyte lipid uptake whilst inhibiting cellular lipolysis. 
With such diverse actions, anything that alters insulin signalling will have a multitude of outcomes. 
 
1.2.3 Free fatty acids and insulin action 
In 1963 Randle proposed that increased FFA availability increased lipid oxidation and was the 
cause of decreased carbohydrate oxidation in the muscle [78]. The proposed mechanism was that 
increased levels of acetyl coenzyme A (acetyl CoA) would inhibit pyruvate dehydrogenase (PDH) and 
increase citrate levels which could inhibit phosphofructokinase (PFK). This would cause reduced 
glycolytic flux and an accumulation of glucose-6-phosphate (G6P), inhibiting hexokinase (HK) and 
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thus reducing glucose uptake from the periphery. However this work was demonstrated in rat 
diaphragm and cardiac muscle, and not human skeletal muscle [78]. More recent work has 
demonstrated that basal respiratory quotient (RQ) in obese and T2DM is actually elevated thus the 
glucose: fat oxidation ratio is raised in such patients; and further work investigating lipid infusions 
during hyperinsulinaemic hyperglycaemic conditions, whilst demonstrating reduced glucose uptake 
[79-81], show no change in glucose oxidation as a percentage of that taken up into the cell [79,80], 
plus reductions in glycogen synthesis associated with decreased glycogen synthase activity [82]. Also, 
hyperglycaemic conditions appear equally able to suppress fat oxidation [83,84]. Additionally, various 
phosphorus-31 (31P) and carbon-13 (13C) nuclear magnetic resonance (NMR) spectroscopy studies 
have identified reduced glucose uptake and glycogen synthesis, reduced intracellular G6P and free 
glucose, plus reduced IRS-1-associated PI3K activity in human skeletal muscle during lipid infusion 
and in insulin resistant groups [85-88]. These findings provide convincing evidence to oppose 
Randle’s original hypothesis.  
 
Recent correlations have been drawn between intramuscular triglyceride (IMTG) accumulation 
and insulin resistance in skeletal muscle [89-92], and other work also demonstrates increased 
intrahepatic triglyceride in insulin resistant states [93-95]. However, it is unlikely that this is a direct 
cause of insulin resistance because skeletal muscle of trained endurance athletes possess high 
oxidative capacity and high insulin sensitivity, despite elevated IMTG [96]. It is likely, therefore, that 
in obesity increased intracellular fat derivatives are the cause of reduced insulin action. Recent data 
indicates that mitochondrial dysfunction in insulin resistance may prevent long-chain fatty acyl 
coenzyme A (LCFAcylCoA) uptake and oxidation, causing cytosolic accumulation of FFA derivatives 
[97]. Hyperinsulinaemic hyperglycaemic conditions (similar to those found in T2DM) produce 
reduced carnitine palmitoyl transferase-1 (CPT-1) activity, the key enzyme in mitochondrial LCFA 
uptake, via increased levels of its inhibitor malonyl CoA [98,99]. There is also evidence of increased 
LCFAcylCoA in muscle biopsy samples taken from insulin resistant rats and humans further 
illustrating their role in the development of insulin resistance [100,101]. Another fat derivative, 
diacylglycerol (DAG), a hydrolysis product of IMTG, has also been shown to be elevated in models of 
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lipid-induced insulin resistance [100,102,103]. Direct effects of LCFAcylCoA and DAG upon insulin 
signalling are documented in muscle and liver, and are known to interfere with protein kinase 
pathways [53,104-106]. Emerging data shows that DAG activates PKC-θ, which has been implicated 
in reduced insulin receptor tyrosine kinase activity and IRS-1 tyrosine phosphorylation, and elevated 
IRS-1 serine phosphorylation [88,100,102,103,107-109]. IRS-1 serine phosphorylation inhibits the 
insulin signal as demonstrated in insulin resistant models [110-113], whilst PKC-θ knockout mice 
models demonstrate protection from fat-induced insulin resistance [114]. Therefore it appears that 
elevated fat derivatives, either from increased adiposity, or induced by diet/infusion, may be a direct 
cause of insulin resistance. 
 
1.2.3 Adipocytokines and insulin action 
As mentioned above, adipose tissue releases several cytokines and hormones. These include 
leptin, adiponectin, tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), resistin, visfatin, 
plasminogen-activator inhibitor-1 (PAI-1), adipsin, acylation-stimulating protein (ASP), 
angiotensinogen, insulin-like growth factor-1 (IGF-1), and transcriptional growth factor-β (TGF-β) 
[52,115]. Amongst these, several have been demonstrated to have direct effects on insulin signalling 
and inflammatory processes in various tissues.  
 
Leptin has several functions including regulating appetite, energy expenditure, thermogenesis, 
maturation and reproduction, and the HPA/thyroid/GH axes [115]. Leptin receptors are found in 
peripheral tissues and the brain [116], and leptin’s signalling pathway via PI3K is shared with insulin, 
providing the potential for interaction [117]. Its serum concentration is directly proportional to fat 
mass [118,119], and is directly correlated with insulin levels [120]. Leptin can reduce tyrosine 
phosphorylation of IRS-1 and reduce IRS-1-PI3K binding [121], an interaction central to the insulin 
signalling cascade. This suggests that hyperleptinaemia may be a direct cause of skeletal muscle 
insulin resistance. In addition leptin has a direct effect on pancreatic β-cells suppressing glucose-
stimulated insulin release [122], further strengthening its role in the pathophysiology of obesity-related 
disease.  
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Adiponectin is specific to adipose tissue and is a product of the most abundant gene transcript in 
adipose tissue [115], yet is downregulated in human obesity and T2DM [123-125]. It augments 
insulin-induced tyrosine phosphorylation of IRS-1 and PKB/Akt in skeletal muscle [126], thus 
promoting the insulin signal. Intravenous administration of adiponectin in hypoadiponectinaemic 
models of obesity results in reduced serum glucose concentrations [126,127] via suppressed 
gluconeogenesis [127], along with increased skeletal muscle fat oxidation [126]. This has been shown 
to involve activation of adenosine monophosphate-activated protein kinase (AMPK) [128], the cell’s 
energy sensing enzyme that regulates nucleic transcription of several genes associated with metabolic 
flux [129]. AMPK activation inhibits acetyl CoA carboxylase (ACC), thus lowering malonyl CoA 
levels, reducing inhibition of CPT1, indicating a possible mechanism for adiponectin-induced 
increased fat oxidation [128]. Adiponectin has also been shown to inhibit endothelial nuclear factor-
κB (NF-κB), a transcription factor that augments insulin resistance and inflammation [130] (see 
Section 1.2.4). 
 
Tumour necrosis factor alpha (TNF-α) is an inflammatory cytokine related to the local 
(adipocyte) and systemic inflammation seen in obesity and T2DM [131]. It is produced mainly by 
macrophages, but is also expressed by adipose and muscle tissue [115]. Its adipocyte expression is 
upregulated with increased adiposity and high-fat feeding [132,133], with insulin resistant individuals 
displaying a negative correlation between serum concentrations of TNF-α and insulin-stimulated 
glucose transport [134]. Several studies show that TNF-α downregulates peroxisome-proliferator 
activated receptor γ (PPAR-γ, a nucleic receptor involved in fat oxidation) gene expression, GLUT-4 
translocation, glycogen synthase and fatty acid synthase activity, and LPL gene expression [115]. In 
addition, TNF-α has been demonstrated to have direct effects on insulin receptor autophosphorylation, 
PKC activity and serine phosphorylation of IRS-1 in muscle tissue and endothelial cells [135-138], 
thus elevated levels may induce insulin resistance and reduce NO-activated smooth muscle relaxation. 
Furthermore, as will be discussed below, TNF-α is also involved in the inflammatory responses seen 
in obese and T2DM states. 
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IL-6 is another multi-functional cytokine primarily involved in inflammatory responses 
produced by fibroblasts, the endothelium, monocytes, macrophages, myocytes and adipocytes [115]. 
Its serum concentration is elevated in obesity [139,140] and T2DM [141], and its expression in 
adipose tissue, which accounts for around 30% of circulating levels [142], is induced by 
catecholamines and TNF-α [115,140,143]. IL-6 appears to have functions in immunology, 
reproduction, bone metabolism, plus roles in glucose and fat metabolism [115]. Recombinant human 
IL-6 infusion increases whole body glucose disposal, yet also increases hepatic glucose production 
(HGP) and elevates FPG [144,145]. IL-6 also decreases adipose tissue LPL activity, whilst increasing 
adipose tissue lipolysis [144,146]. Increased hepatic triglyceride excretion in IL-6 infused rats has 
been attributed to the increased availability of FFA from adipose tissue as a result of IL-6 induced 
adipose tissue lipolysis [147]. Further work shows that circulating levels of IL-6 and adipose tissue IL-
6 content are inversely correlated with insulin sensitivity [139,148,149], and a gene polymorphism 
leading to reduced IL-6 levels has been shown to be related to reduced area under the curve following 
oral glucose tolerance test, reduced insulin concentrations and improved insulin sensitivity [150]. 
 
This brief account illustrates that various adipose-derived moieties can have direct effects on 
insulin signalling, and indirect effects on factors associated with metabolic flux. Many of these are 
upregulated in obesity (with the exception of adiponectin, which is downregulated) and impede the 
insulin signal, and therefore, in the event of increased adipose mass, increased adipocytokine levels 
can induce insulin resistance. 
 
1.2.4 Inflammation and insulin action 
In addition to direct effects on muscular and hepatic insulin signalling, fat moieties and 
adipocytokines are also involved in local and systemic inflammation and vascular dysfunction. This is 
particularly relevant to the low-grade systemic inflammation seen in obesity and T2DM [151]. 
Potential links between inflammation and metabolic disease were first demonstrated in 1876 by 
Ebstein who showed that sodium salicylate (the active component in aspirin) diminished glucosuria in 
diabetic patients [152]. However, it was not until the 1950s and 60s that relationships between 
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inflammation and T2DM or obesity were recognised [153-155]. Recent epidemiological studies now 
confirm such relationships, showing positive correlations between T2DM and markers/mediators of 
inflammation and acute-phase reactants such as fibrinogen, C-reactive protein (CRP), IL-6, PAI-1 and 
white cell count [156-161]. In addition, lifestyle intervention in the Diabetes Prevention Programme 
reduced markers of inflammation and coagulation in IGT individuals, concomitantly with a reduced 
risk of developing T2DM [162]. 
 
The current evidence base illustrates that TNF-α, FFAs and their metabolites, and reactive 
oxygen species (ROS, systemic markers of oxidative stress), can each activate the c-Jun N-terminal 
kinase (JNK) pathway, and the IκB kinase-β (IKK-β) pathway (producing NF-κB) [163,164]. The 
JNK and IKK-β pathways are both involved in inflammation-induced insulin resistance, yet via 
different mechanisms. JNK promotes serine phosphorylation of IRS-1 [165-167], thus diminishing the 
intracellular insulin signal, whereas IKK-β activation liberates the transcription factor NF-κB for 
translocation into the nucleus, where it regulates expression of genes directly involved in insulin 
resistance and the atherosclerotic process [163,168]. The activity of JNK and IKK-β is elevated with 
increased adiposity [166,169,170], and in addition to the above, they have also been shown to be 
activated by advanced glycation end-products [171-173], illustrating the association of 
hyperglycaemia with inflammatory mechanisms.  
 
Inflammation is an important aspect of insulin resistance. Adipose tissue appears to be a key 
instigator of inflammatory processes locally and in other tissues such as the liver, the endothelium and 
muscle. In addition, the liver produces pro-inflammatory cytokines (e.g. TNF-α and IL-6) under 
elevated FFA conditions and during steatosis [170] (e.g. non-alcoholic fatty liver disease (NAFLD)) 
via activation of NF-κB. These also propagate local and extra-hepatic (muscle and endothelial) 
inflammation, leading to insulin resistance [170]. 
 
1.2.5 Insulin and capillary perfusion 
Recent data have suggested that endothelial dysfunction may impair capillary perfusion of 
skeletal muscle, reducing its exposure to metabolic substrates, hormones and oxygen [174-176]. 
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Endothelial nitric oxide synthase (eNOS) is necessary for smooth muscle relaxation via the production 
of NO [76]. Endothelial insulin signalling (via IRS-1 and PKB/Akt) upregulates eNOS activity, and 
thus insulin is involved in smooth muscle tone and vasodilatation, allowing increased blood flow and 
perfusion of the tissue [76]. Recent data from Clerk et al (2006) shows that in obesity, insulin causes 
sub-optimal microvascular perfusion in skeletal muscle [177]. Also, research by Laakso et al (1990) 
reports reduced skeletal muscle blood flow in obese and T2DM patients compared with controls [178],  
whilst further work from Kashyap et al (2005) shows that eNOS activity is impaired in T2DM patients 
[179]. Furthermore, other work demonstrates reduced insulin-mediated capillary perfusion following 
infusion of lipid [180] or TNF-α [181]. More recent work from Naruse et al (2006) demonstrates the 
involvement of PKC in reduced endothelial NO production in the obese [182], therefore increased 
FFA availability in obese states might mediate insulin resistance in endothelial cells by similar 
mechanisms to those discussed above in skeletal muscle. Additionally, the role of inflammation is also 
important in the capillary perfusion process. TNF-α, oxidised LDL, and lysophosphatidic acid 
(produced by platelets) all increase nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 
activity [183], an enzyme involved in the production of superoxide anions, which react with NO 
reducing its bioavailability, and thus reducing NO-induced vasodilatation [183,184]. Ultimately, sub-
optimal microvascular perfusion shall reduce the availability of insulin and glucose to the skeletal 
muscle, thus reducing insulin-stimulated glucose uptake.  
 
1.2.6 Overview of insulin resistance 
This introduction reflects that insulin resistance is largely determined by the level of adiposity. 
Whilst the two are closely related, insulin resistance arises in many other conditions besides obesity 
and T2DM, sometimes independently of body mass (for example, acromegaly, polycystic ovary 
syndrome (PCOS), Cushing’s disease, NAFLD, pregnancy, puberty, lipodystrophy, Prader-Willi 
syndrome, and others [185]). As described above, adipose tissue may act as a buffer for daily lipid 
flux. In obesity, FFAs are released into the systemic circulation in great excess of their oxidative 
needs. In lipodystrophy, at the other extreme of adipose mass, severe insulin resistance arises, and 
high levels of IMTG and FFA metabolites are also documented [186]. Therefore it is likely that in the 
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absence of adipose tissue, the circulation, liver and muscle tissue may become the major triglyceride 
stores, and insulin resistance arises due to the mechanisms discussed above [187]. In animals, fat 
transplantation into lipodystrophic models, vastly improves insulin sensitivity, and reduces IMTG 
levels [187,188]. Whilst this illustrates that increased adiposity is not the whole story, this must not 
lessen the importance of its effects. It is clear that FFAs and adipocytokines are key to the 
development of skeletal muscle and hepatic insulin resistance, in addition to having direct effects upon 
endothelial insulin signalling and vascular function via inflammatory responses. 
 
Insulin resistance not only occurs at the level of the tissue (muscle or liver) but also in the 
vascular endothelium, where an inability of insulin to reduce vascular tone decreases microvascular 
perfusion and thus the delivery of hormones and nutrients to the muscle tissue. Increased adipose-
derived moieties (FFAs, DAG or adipocytokines) may activate a serine/threonine kinase cascade, 
initiated by PKC, JNK, or IKK-B, leading to IRS serine phosphorylation, which reduces IRS-1-PI3K 
association and therefore causes reduced activation of insulin-stimulated events downstream of PI3K. 
Whilst this section has concentrated on the environmental input that causes insulin resistance (i.e. the 
positive energy balance leading to obesity), several gene defects have been identified that predispose 
to the development of T2DM [9,189]. However, genetic evolution cannot explain the recent escalating 
trends in metabolic abnormalities, given the short time course in which this has occurred. Thankfully, 
epidemiological evidence shows that lifestyle (diet and exercise) intervention can substantially reduce 
the risk (up to 67%) of T2DM [190-194]. 
 
1.3 Treatment interventions for insulin resistant conditions 
T2DM and the metabolic syndrome can be treated with pharmaceutical aids [195-199], one of 
the reasons for the large proportion of the NHS budget spent on diabetes healthcare. Lifestyle also has 
a large impact on the metabolic impairments of metabolic disease [200]. Exercise and dietary 
manipulation have been demonstrated to have beneficial effects on the major symptoms of the 
metabolic syndrome [200] (adiposity, dyslipidaemia, hypertension and hyperglycaemia) and on 
glycaemic and lipaemic control in diabetic patients [200]. For example, several epidemiological 
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studies have shown hypocaloric diets and/or increased levels of physical activity to be effective in 
reducing symptoms of the metabolic syndrome, improving insulin sensitivity via reduced HGP, and in 
improving endothelial function via reduced systemic inflammation [191,201-203]. In addition, 
evidence further supports the use of pharmaceuticals and/or lifestyle intervention for affected patients 
in order to prevent or delay the onset of cardiovascular disease in at risk individuals [191,204-208]. 
Furthermore, recent epidemiological evidence from various diabetes prevention studies (e.g. the 
American Diabetes Prevention Project (DPP) [191], the Finnish Diabetes Prevention Study (DPS) 
[209], the Chinese Da Qing IGT study [193] and a Japanese study [190]) indicate that long-term 
dietary and exercise intervention can not only reduce the incidence of diabetes by up to 67% 
[190,191,193,209], but also provides a more powerful stimulus than metformin, a routine drug 
administered to T2DM patients [194]. The DPP demonstrated that lifestyle (diet and exercise) 
alteration reduced the incidence of diabetes more so than treatment with metformin alone in obese IGT 
individuals (Figure 1.4). 
 
Figure 1.4 –The Diabetes Prevention Project  
3234 obese IGT individuals were followed for a period averaging 2.8 years with placebo or 
metformin (2 x 850 mg.day-1) or lifestyle intervention (goal - 7% weight loss plus > 150 min.week-1 
exercise). Graph (i) shows the change in diabetes incidence over 4 years. Lifestyle modification had a 
greater effect (58% reduction) than metformin (31% reduction). Graph (ii) demonstrates the marked 
weight loss following lifestyle alteration compared with metformin administration. Adapted from 
Knowler et al (2003) New Eng J Med 346(6):393-403[194]. 
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There is clear evidence from epidemiological trials in several countries (UK, US, Finland, 
Japan, China) that reversal and prevention of metabolic disease and reduction of CVD risk is possible. 
The data is particularly interesting as besides the direct health benefits it appears that part of the 
economic burden to healthcare systems may be relieved by patient lifestyle alteration, a relatively low-
cost intervention. However, despite this convincing evidence base that diet and exercise are key tools 
in the prevention and reversal of human metabolic disease, trends in obesity, diabetes and CVD 
continue to escalate (see section 1.1). Therefore, the currently known effective regimes are either not 
being prescribed, or are not being adhered to, or there is a lack of public awareness. In addition to 
improving the communication of the health benefits of lifestyle changes, we could also search for 
novel therapeutics or interventions that may be more easily carried out by the target group. This thesis 
investigates some recent alternative approaches to factors associated with insulin sensitivity and the 
metabolic syndrome. The following two sections (1.4 and 1.5) of this literature review summarise the 
background knowledge to the key areas investigated in this project.  
 
1.4 Measuring insulin sensitivity 
The concept of insulin sensitivity describes the efficiency with which insulin can regulate its 
functions following a perturbation (e.g. meal ingestion) to the system [185]. Insulin sensitivity follows 
a continuum where insulin resistant individuals such as T2DM and metabolic syndrome patients have 
low insulin sensitivity [185]. As described in Section 1.3 various lifestyle or pharmaceutical 
interventions affect the extent of insulin resistance, therefore it is important that a valid and reliable 
tool for measuring insulin sensitivity is available for clinicians and academic researchers to further 
explore the mechanisms that lead to insulin resistance, and to develop appropriate treatment regimes. 
 
The glycaemic clamp protocol, devised in 1966 by Andres et al and further developed by 
Defronzo et al (1979), is a technique whereby insulin and glucose are simultaneously infused at 
known rates [210,211]. Hyperinsulinaemia is maintained so as to maximise peripheral tissue glucose 
uptake and suppression of HGP, whilst euglycaemia is controlled at the patients individual FPG level 
[211]. The amount of glucose infused equals the amount of peripheral tissue glucose uptake, thus 
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providing an insulin sensitivity index (ISI; ISICLAMP) [211]. Prior to this insulin tolerance tests (ITT) 
and intravenous glucose tolerance tests (IVGTT) were often used. The ITT was first documented in 
1929 by Horgaard et al [212]. This involves a single intravenous (IV) insulin injection and the 
monitoring of blood glucose in the post-injection hypoglycaemic period, and an ISI (ISIITT) is derived 
from the disappearance of glucose in the blood [213,214]. The injected insulin bolus suppresses HGP, 
and thus the ISIITT gives a peripheral measure of insulin sensitivity [213-215]. The major drawback to 
the ITT is that the ensuing hypoglycaemia creates undesired symptoms for the patient – cold, nausea, 
sweating, delirium – and reports of cardiac arrhythmia have been documented [216,217]. The IVGTT 
is a further technique involving a single IV injection, but of glucose, intended to replicate postprandial 
conditions. Once again, the subsequent changes in glucose concentrations are monitored and an ISI 
(ISIIVGTT) is derived from the disappearance of glucose from the systemic circulation [185,218]. As 
mentioned in Section 1.1, the OGTT is the main technique used in the diagnosis of diabetes. However, 
several research groups have derived ISIs based on glucose and insulin concentration data from 
frequently-sampled plasma following a 75 g OGTT [219-223]. These provide a whole body ISI 
estimate (ISIOGTT) since the postprandial glucose response involves both hepatic and peripheral tissue 
contributions. In addition to these dynamic tests involving glucose/insulin 
ingestion/infusion/injections, a number of ISIs have been derived from data in the basal state. The 
homeostatic model assessment (HOMA) and the quick insulin sensitivity check index (QUICKI) both 
derive an ISI from FPG and fasting serum insulin (FSI) concentrations [224,225]. These are very 
simple and rapid tests that are often applied to epidemiological studies. It is documented that because 
FPG is determined by HGP, ISIHOMA and ISIQUICKI are estimates of hepatic insulin sensitivity  
[224,225]. 
 
The clamp technique allows precise control of insulin and glucose at known low, normal or high 
levels and can easily be combined with other methodologies (e.g. tracer infusions, magnetic resonance 
imaging (MRI), positron emission tomography (PET)) to isolate various components of insulin 
sensitivity, such as peripheral or hepatic sensitivity, glycogen synthesis, or lipolysis [86,226-228]. 
This makes it the most useful technique for the measurement of insulin sensitivity, and so has become 
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the “gold standard” tool. However, the clamp technique is not suitable in non-clinical environments 
where a clinician is not on-hand to provide medical assistance, and a complicated set-up involving 
infusion pumps, insulin preparation, on-line glucose analysis, and computer algorithms to calculate 
glucose infusion rates, makes the clamp available only to specialised laboratories [211]. Additionally, 
the clamp, along with several other techniques, use glucose and insulin injections/infusions that create 
non-physiological (i.e. prolonged elevation or supraphysiological concentrations) situations that are 
not representative of free-living situations. A drawback of the techniques involving glucose/insulin 
infusions/injection (e.g. clamp, ITT and IVGTT) is that they are gut-independent. The literature 
suggests that several gut peptides (e.g. glucose-dependent insulinotropic peptide (GIP), 
cholecystokinin (CCK), PYY3-36 and ghrelin), released in response to feeding, have effects on energy 
homeostasis, including pancreatic insulin release, and even direct effects on glucose metabolism 
[229,230]. Gut-dependent techniques, such as the OGTT may therefore provide a more physiological 
ISI estimate that incorporates all tissues involved in glucose metabolism into the measure of insulin 
sensitivity.  
 
Due to the difficulties in acquiring clinical support the clamp is not readily available in our 
laboratory. The OGTT is a tool of interest because it is gut-dependent, it does not artificially control 
insulinaemia or glycaemia, and it simulates meal ingestion. ISIs from the OGTT (and ITT, IVGTT, 
and HOMA [214,218,224,225]) have been validated against the gold standard hyperinsulinaemic 
euglycaemic clamp protocol [219-223]; however, the reliability of several techniques is unknown. 
Reliability (i.e. the consistency of repeated measures) of FPG and 2h-PG data from OGTT protocols 
and ISIHOMA estimates have been assessed and is found to be poor [224,231-234], yet pre-test 
conditions such as diet and physical activity, two factors that can influence glucose metabolism and 
insulin sensitivity, were not controlled, thus prompting further work in this area. Another drawback of 
the OGTT is that it gives a whole body ISI and cannot isolate hepatic from peripheral insulin 
sensitivity, nor is the rate of appearance of glucose from endogenous and exogenous sources known. 
For these reasons, we wish to test the reliability of OGTT-derived ISIs following controlled pre-test 
conditions, in order to establish the best ISI for use in dietary or exercise research interventions; and to 
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apply isotopic glucose tracers to OGTT protocols to enable quantification of gut- and liver-derived 
glucose appearance. 
 
1.5 Alternative interventions on the impairments seen in metabolic 
disease  
 
Either the message regarding health risks of inactivity and obesity is not being effectively 
communicated to the public, or the public perception is that the effort required to improve their health 
is too high. Therefore, developing alternative treatment strategies to relieve symptoms of metabolic 
disease is sensible. Such strategies may include dietary supplementation, meal frequency, and exercise 
timing. 
1.5.1 Cinnamon spice 
The first paper to illustrate potential hypoglycaemic effects of cinnamon was from Khan et al in 
1990, who demonstrated that amongst a number of spices, cinnamon showed the greatest effect in a rat 
adipocyte glucose utilisation assay [235]. These findings were confirmed more recently by Broadhurst 
et al (2000) and Jarvil-Taylor et al (2001) in 3T3-L1 cell lines [236,237]. In 2003 the first human 
publication became available. Khan et al (2003) demonstrated that 1, 3, or 6 g of Cinnamomum cassia 
spice per day for 40 days can reduce FPG, total cholesterol and LDL-c by up to 29% in T2DM patients 
[238]. Since this publication two further human data sets became available from Mang et al and 
Vanschoonbeek et al [239,240]. Mang et al (2006) showed similar findings to Khan, but with no 
effects on haemoglobin A1c (HbA1c) using a 4 month 3 g.day-1 intervention in T2DM patients [239]. 
Vanschoonbeek et al (2006) using a 1.5 g.day-1 intervention over 6 weeks found no effect of cinnamon 
in a postmenopausal T2DM group, thus provoking some controversy regarding the effects of 
cinnamon [240]. The in vitro and animal evidence however is more convincing. Cinnamon’s phenolic 
extract may upregulate insulin receptor autophosphorylation, suppress phosphotyrosine phosphatase 
(PTP-1) inhibition of the insulin receptor, and downregulate glycogen synthase kinase-3β (GSK-3β) 
activity, thus improving the intracellular insulin signal [241]. Roffey et al (2006) also recently showed 
increased glucose uptake by a phosphoinositol-3-kinase (PI3K) dependent mechanism in 3T3-L1 cell 
lines, yet downregulated adiponectin expression, an adipocytokine associated with improved insulin 
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sensitivity, thus complicating the mechanisms [242]. In rats, evidence from Qin et al (2003) has shown 
that long-term cinnamon ingestion can improve fructose-induced insulin resistance via an eNOS 
dependent mechanism, suggesting improvement in endothelial function, whilst increasing skeletal 
muscle insulin receptor substrate-1 (IRS-1) phosphorylation and association with PI3K, important 
interactions in insulin signalling [243,244]. Further work in mice has demonstrated increased insulin 
receptor and IRS-1 phosphorylation, increased GLUT-4 translocation, plus reduced fasting glucose, 
total cholesterol and triglycerides, further illustrating the positive effects of cinnamon supplementation 
[245,246]. Nevertheless, despite the convincing in vitro and in vivo animal evidence, the picture in 
humans is less clear, and further work is warranted. The acute effects of cinnamon ingestion, and their 
persistence, are unknown, and at the time of planning experimental work, only Khan’s publication was 
available, and therefore effects on insulin sensitivity were also unknown.  
 
1.5.2 Ghrelin and feeding frequency 
Ghrelin, a 28 amino acid peptide hormone isolated from the oxyntic glands of the stomach, was 
discovered in 1999 as a ligand for the pituitary growth hormone secretagogue receptor (GHS-R) [247]. 
Since its discovery over 1200 papers have been published investigating ghrelin’s targets and effects, 
and it is now clear that ghrelin has several endocrine and non-endocrine effects [248]. Perhaps the 
most well documented function is in appetite regulation in the arcuate nucleus (ARC) and 
ventromedial nucleus (VMN) in the hypothalamus [248]. Plasma ghrelin concentrations follow a 
diurnal rhythm, peaking between midnight and dawn, with pulsatile day-long responses [249], peaking 
prior to meal ingestion and falling in the postprandial period [250-252], suggesting a role for ghrelin in 
altering hunger before and after ingesting food. Ghrelin responses to meal ingestion are found to 
reciprocate insulin responses [253], and various data support the theory that insulin is required for 
postprandial ghrelin suppression [254-258]. This interaction is less pronounced in T2DM patients 
[259], evidence that insulin resistance may interfere with ghrelin’s response and action. Interestingly, 
Tschop et al (2001) demonstrated that ghrelin is downregulated in obese and Pima Indian T2DM 
individuals [260], with Poykko et al (2003) confirming these findings in insulin resistant individuals 
[261].  
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Besides its GHS action and orexigenic effects in the hypothalamus, ghrelin has also been 
implicated in a large number of metabolic and endocrine functions: energy balance, sleep and 
behaviour, gastric motility and acid secretion, exocrine and endocrine pancreatic function, glucose 
metabolism, cardiovascular actions and immune function [248]. Ghrelin’s effects on metabolism are 
particularly relevant to metabolic disease especially given its downregulation in insulin resistant states. 
In 2005 Barazzoni et al demonstrated that ghrelin regulates mitochondrial lipid metabolism gene 
expression and fat distribution in liver and skeletal muscle [262]. Furthermore, Tschop et al (2000) 
and Thompson et al (2004) have shown that ghrelin induces adipogenesis [263,264], and Wortley et al 
(2004) have shown that ghrelin deletion increases fat utilisation [265], which provides further 
evidence for ghrelin’s involvement in metabolic flux. This concept is poorly understood in humans 
and warrants further investigation. In this thesis, pre- and postprandial changes in insulin and ghrelin 
concentrations are investigated under different feeding regimes to further explore the insulin-ghrelin 
relationship. 
 
In addition, this thesis also investigates feeding frequency. An abundance of papers can be cited 
for the effects of meal composition and caloric content on insulin resistance and metabolic 
abnormalities, yet the concept of meal frequency or snacking is an area that is relatively under 
represented in the literature [266]. This is surprising given the epidemiological studies of European 
men and women demonstrating that snacking and light meals contribute to 25-35% of the daily energy 
intake (EI) and that obesity is related to increased snacking [267,268]. The current studies investigate 
diets of mixed composition (50-80% carbohydrate, 10-35% fat) fed up to 17 times in a day for 1 to 
130 days in various animal and lean, obese and T2DM human cohorts. The evidence base is mixed 
with regards to metabolism, with the various studies showing positive, negative and null effects of 
increased meal frequency [269-281]. For example, in humans Bertelsen et al (1993) showed that 
following 6- versus 2-meal isocaloric feeding regimes, increased meal frequency decreased day-long 
glucose, insulin and free fatty acid concentrations [269]. In contrast, Farshchi et al (2005) 
demonstrated increased insulin, LDL-c, and EI, with reduced thermogenesis following 14 days of 
increased meal frequency [271]. Finally, Murphy et al (1996) compared 12 versus 3 isocaloric meals 
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per day for 2 weeks and showed no changes in lipaemia (including LPL activity), glycaemic control or 
insulin [272]. As a result, no clear conclusions can be drawn from the literature as to the optimum 
feeding frequency regime. 
 
As described above, ghrelin and its involvement in metabolism has become a research focal 
point. In 2002 Sugino et al presented some data investigating the effects of mixed-meal frequency on 
ghrelin responses in sheep [282]. Following a 12 hour intervention with 2 meals, 4 meals, or ad 
libitum feeding, increased meal frequency inversely correlated with ghrelin area under the curve [282]. 
In addition, they confirmed the preprandial surges in ghrelin that were documented in previous 
literature, and they demonstrated reduced peak preprandial ghrelin concentrations with increasing 
meal frequency [282]. Given ghrelin’s involvement with satiety and metabolic flux, these findings 
may suggest that increased meal frequency suppresses appetite and reduces adipogenesis thus 
promoting fat oxidation. However EI was not controlled in Sugino’s paper and was different between 
trials, so the different ghrelin response could be due to different calorie intake or different feeding 
frequency between trials [282]. Similar evidence is not available in humans. Therefore we intend to 
investigate the ghrelin response to different feeding regimes that are isocaloric.  
 
1.5.3 Exercise and postprandial lipaemia 
Following a meal, triglycerides in intestinally-derived chylomicrons and hepatically-derived 
VLDL compete for the same saturable pathway to be hydrolysed by lipoprotein lipase (LPL), an 
endothelial lipase found in the capillary bed of peripheral tissues (adipose and skeletal muscle) 
[283,284]. During this period, elevated circulating triglyceride-rich moieties increase the opportunity 
for lipid exchange with cholesterol-rich lipoproteins, leading to a depletion of HDL-c and a decrease 
in the size of LDL, creating a lipaemic profile that is more atherogenic [285]. In addition, during the 
postprandial period changes in lipid metabolism can increase blood coagulability [286], and fat 
ingestion per se can induce endothelial dysfunction [287,288]. Fortunately, such changes in the 
healthy human are transient. However, during a normal day when several meals are ingested, 
postprandial elevation of triglyceride-rich moieties does not completely recover prior to subsequent 
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meals, and if lipoprotein metabolism is impaired, for example in obesity or insulin resistance, levels of 
triglyceride-rich lipoproteins may be persistently elevated resulting in increased reverse-cholesterol 
transport and endothelial dysfunction [289]. Furthermore, a number of studies demonstrate that 
impaired lipoprotein metabolism is implicated in the development of atherosclerosis [290-299], so 
reducing postprandial lipaemia may reduce CVD progression. 
 
Physical activity has a large effect on lipid metabolism, and cross-sectional studies indicate that 
endurance-trained athletes have decreased postprandial lipaemia and increased triglyceride clearance 
compared with untrained controls [300-305]. This may be partly explained by increased muscle mass 
and vascularisation, hence increased exposure to the target tissue and capillary bed LPL in athletes. 
However, when athletes are studied more than 2 days following their last training session, no 
differences exist compared with controls, thus effects of activity on triglyceride metabolism are only 
transient and quickly reversed [306,307]. Acute effects of exercise on postprandial lipaemia have been 
demonstrated by several groups, and they appear to be delayed and transient with no demonstrable 
effects when exercise is performed less than 1 hour, or as long as 48 hours, before feeding [308-311]. 
The acute effects of exercise also appear to be related to energy expenditure, as studies comparing 
various exercise bouts in untrained individuals, e.g. 3 x 30 min versus 1 x 90 min [312], 3 x 10 min 
versus 1 x 30 min [313], 90 min at 60% VO2max versus 180 min at 30% VO2max [309], show similar 
effects on postprandial lipaemia.  
 
As a therapeutic tool, exercise has a pronounced effect on lipaemia. However, we know little 
about the timecourse; how long after exercise is the beneficial effect preserved?  Moreover, what is the 
optimum time delay between exercising and feeding to see the biggest effect? Therefore one aspect of 
this thesis was to investigate the time post-exercise when the beneficial effect on postprandial lipaemia 
is lost. 
 
 
 
 24
1.6 Overview and experimental aims of this thesis 
This literature review illustrates the current impact of insulin resistance and its involvement in 
many diseases. In addition, it has highlighted some possible future research directions. As explained in 
Section 1.1, trends in obesity and its associated diseases appear to be escalating despite a wealth of 
knowledge that lifestyle modification can alleviate the onset of such diseases. Therefore, the aim of 
this PhD project was to provide new information regarding dietary supplementation, feeding 
frequency, and exercise timing, that may improve existing therapeutic strategies.   
 
As described in Section 1.4, a valid and reliable tool is required to measure insulin sensitivity. 
Chapter 3 investigates the reliability of validated OGTT-derived ISI estimates due to an absence of 
such data in the literature. The application of stable isotopic tracers to OGTT protocols was also 
highlighted as a useful tool for determining glucose appearance. Chapter 4 displays pilot work 
investigating the quantification of glucose appearance from the gut and the liver during OGTT 
protocols. Section 1.5.1 illustrated that cinnamon may be a useful therapeutic for impaired glycaemic 
control, yet evidence in humans is mixed and quite limited. Chapters 5 and 6 make use of one of the 
OGTT-derived ISI indices to investigate the effects of acute and chronic cinnamon spice 
supplementation upon insulin sensitivity. In Section 1.5.2, the concept of feeding frequency and the 
possible involvement of a novel GI peptide, ghrelin, was discussed. Feeding frequency was shown to 
have mixed results on symptoms of the metabolic syndrome, and recent evidence linked postprandial 
insulin responses to postprandial ghrelin responses, an association shown to be diminished in T2DM. 
Chapter 7 investigates the effect of feeding frequency upon insulin and ghrelin responses. Finally, 
Section 1.5.3 described the literature surrounding the effects of physical activity upon postprandial 
lipaemia. Exercise was clearly shown to have a delayed and transient effect on triglyceride levels in 
several studies, however the exact time course of this effect has not been established. Chapter 8 
presents data which explores the time delay between exercise and a high fat meal. The aim of this 
study is to ascertain when the beneficial effect of exercise on lipaemic control is lost.  
 
 25
These topics were chosen after close scrutiny of the literature to identify gaps in the evidence 
base, or to discover possible novel therapeutics that may be useful in the prevention of metabolic 
disease. In all studies, a lean but sedentary group was used to study the effects of the intervention. 
Such subjects are readily-available in our working environment, and were primarily used to assess the 
potential effects of the intervention prior to further work in patient cohorts. 
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2. General Methods 
___________________________________________________________________________ 
 
 
The following chapter describes techniques, assays and calculations that are relevant to more 
than one of the experiments presented in this thesis. This is to avoid unnecessary replication of 
common methods. 
2.1 Ethical approval 
 
All investigations described were granted ethical approval by the Safety and Ethics 
Subcommittee of the School of Sport and Exercise Sciences. Verbal and written explanations of the 
experiments were given to all potential subjects. Written consent was obtained from all subjects, who 
were aware that as volunteers they were free to withdraw from the experiment at any time. 
2.2 Blood sample collection 
Through the written and verbal explanation of the experiment the subjects were requested to 
attend on the morning of the investigation having avoided physical activity, because even light 
physical activity would alter metabolism. Prior to all studies subjects were rested (seated) for 10 
minutes, before a resting blood sample was taken from an antecubital vein. Whole blood samples were 
collected into appropriate vacutainers (BD Vacutainers, Oxford, UK) – non-anticoagulant for serum 
insulin measurements, sodium fluoride for plasma glucose measurements, and EDTA for plasma 
ghrelin, triglyceride, and glycerol measures. EDTA vacutainers for ghrelin analysis were pre-treated 
with 30 µl of the serine protease inhibitor apoprotinin (Sigma, UK) per 300 µl plasma. All samples 
were kept on ice at 4 oC for no more than 30 min prior to plasma/serum separation. Vacutainers were 
centrifuged at 3000 g for 10 min at 4 oC, and their plasma/serum constituent separated and stored in 
1.5 ml microtubes (Eppendorf UK Ltd, Cambridge, UK) at -70 oC for later analysis.  
2.3 Assays 
 
All samples were measured in duplicate and the intra-assay coefficient of variation for each 
measure is shown in Table 2.1 
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Table 2.1 – Intra-assay coefficient of variation for each measure in each study  
 
2.3.1 Glucose  
 
2.3.1.1 Hexokinase method 
 
Plasma glucose concentrations were measured using a COBAS Mira Plus (ABX Diagnostics, 
Montpellier, France) automated analyser, by an enzymatic assay involving hexokinase and glucose-6-
phosphate dehydrogenase and measuring absorbance changes at 340 nm. A 27.8 mmol.l-1 calibrator 
solution and normal (5.15 mmol.l-1) and pathological (14.07 mmol.l-1) human quality control sera 
(ABX Diagnostics, Montpellier, France) were used. Automated dilutions of the calibrator were made 
to construct a standard curve. 
 
2.3.1.2 Gas chromatography mass spectrometry (GC-MS) 
Prior to GC-MS analysis all samples were deproteinised and derivatised as follows. A 100 µl 
aliquot of plasma was added to 1 ml of acetone, vortexed and set in ice for 15 min. This mixture was 
centrifuged at 3000 g at 4 oC for 15 min and the supernatant evaporated under nitrogen gas at 20 oC. 
The pellet was resuspended in 160 µl of a 1:1 ethylacetate:heptafluorobutyric acid anhydride stock and 
Assay Chapter Intra-assay CV (%)
Glucose 3 3.51
4 3.51
5 2.40
6 1.53
[6,6-2H2]-glucose enrichments 4 3.69
[U-13C]-glucose enrichments 4 2.50
Insulin 3 4.12
4 4.12
5 5.77
6 4.38
7 5.34
Ghrelin 7 3.66
Triglyceride 8 2.04
Glycerol 8 3.64
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incubated at 70 oC for 60 min. The solution was centrifuged at 3000 g at 25 oC for 5 min and then 
evaporated under nitrogen gas again at 20 oC. The sediment was resuspended in 70 µl of ethylacetate, 
vortexed, left at room temperature for 15 min and then transferred to a vial ready for gas 
chromatography analysis. (All chemicals obtained from Sigma, UK.) 
 
The [6,6-2H2]- and [U-13C]glucose enrichments were determined by GC-MS analysis of the 
heptafluorobutyrate derivatives of glucose on Agilent Technologies GC and mass selective detectors 
(GC – Agilent Technologies 6890N, UK; Mass selective detector - Agilent Technologies 5973, UK). 
Ion masses of 519 (molecular ion mass, M), 521 (M+2), and 525 (M+6) were selectively monitored 
for [6,6-2H2]- and [U-13C]glucose enrichments. Standard enrichment curves ranging 0, 0.5, 1, 1.5, 2, 
2.5, and 3 were constructed. 
 
2.3.2 Insulin  
 
Serum insulin concentrations were determined using a commercially available enzyme-linked 
immunoabsorbant assay (ELISA) kit (DRG Instruments GmbH, Germany), by a solid-phase two-site 
direct sandwich technique. Absorbance changes were measured at 450 nm. Standards ranging 0, 6.25, 
12, 25, 50, and 100 µU.ml-1 and human control sera (Bio Rad LyphochekTM Immunoassay control 
sera, DRG, Germany) were used. No cross-reactivity with proinsulin is reported by the manufacturer. 
 
2.3.3 Ghrelin 
Plasma ghrelin was measured by a competitive 125I-peptide radioimmunoassay (RIA) on 
unextracted plasma using a commercially available kit (Phoenix Peptides, California, US). A gamma-
counter was used to measure counts per million of the samples and standards (1, 2, 4, 8, 16, 32, 64, 
and 128 pg.tube-1). A standard curve of ghrelin concentration versus bound/free peptide (B/Bo %) was 
constructed using the following:  
( ) 100
NSBTB
NSBCPM%Bo
B ×−
−=             [2.1] 
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Where CPM = gamma counts per million of the standard, NSB = CPM of non-specific binding, 
and TB = CPM of total binding. This assay involves antibodies raised against the C-terminal region, so 
values stated are for total ghrelin: des-acylated plus octanoylated circulating peptides. Relevant 
guidelines for the handling of radioactive compounds were followed. No controls were used in this 
assay. Discrepancy is found between the two commercially available kits from Phoenix Peptides and 
Linco Research Inc [314]. The two show strong correlation yet the Linco kit measures a factor of 10 
higher than the Phoenix kit, and thus there is poor agreement between the two [314]. The majority of 
previous publications employ the use of Phoenix over Linco, however no information is currently 
available as to which is the more accurate measure. 
 
2.3.4 Triglyceride 
Plasma triglyceride concentrations were measured using a COBAS Mira Plus automated 
analyser (ABX Diagnostics, Montpellier, France), by an enzymatic assay involving lipase, glycerol 
kinase, glycerol-3-phosphate oxidase and peroxidase, while measuring absorbance changes at 505 nm. 
Normal and pathological human quality control sera (ABX Diagnostics, Montpellier, France) and 
standards ranging 0, 572, 1145, and 2290 µmol.l-1 were used. Because this assay quantifies 
triglyceride by measuring glycerol in the sample after lipolysis of the triglyceride with lipase, the 
triglyceride measures were corrected for free glycerol (see Section 2.3.5). 
 
2.3.5 Glycerol 
Prior to analysis samples were deproteinised: 300 µl plasma was added to 30 µl of 1 mol.l-1 
sulphosalicyclic acid, mixed, and put on ice for 20 min, then centrifuged for 5 min at 3000 g at 4 oC to 
separate the supernatant into a fresh tube. Plasma glycerol concentrations were measured using a 
COBAS Mira Plus automated analyser (ABX Diagnostics, Montpellier, France) by an enzymatic assay 
involving glycerol kinase, pyruvate kinase and lactate dehydrogenase, while measuring absorbance 
changes at 340 nm. Glycerol control solution (Sigma, UK) at 573 µmol.l-1, and standards ranging 0, 
115, 229, 458, and 1145 µmol.l-1 were used. 
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2.4 Calculations 
 
2.4.1 Insulin sensitivity 
 
Oral glucose tolerance tests (OGTTs) involved consuming 75 g of glucose dissolved in 300 ml 
of water.  Five previously derived insulin sensitivity indices based on OGTT models were used in this 
thesis: Matsuda (1999), Stumvoll (2000), Soonthornpun (2003), Cederholm (1990), and Belfiore 
(1998) [219-223]. These were calculated as follows: 
MSIMPGFSIFPG
10000 ISI MatsudaOGTT ×××=  [2.2] 
 
( ) ( ) ( )PGmin900037.0ISh2000064.0BMI0032.0226.0 ISI StumvollOGTT −×−−×−×−=  [2.3] 
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      [2.5] 
[2.6] 
 
Where FPG = fasting plasma glucose in mg.dl-1, FSI = fasting serum insulin in µU.ml-1, MPG = 
mean plasma glucose following OGTT in mg.dl-1, MSI = mean serum insulin following OGTT in 
µU.ml-1, BMI = body mass index in kg.m-2, 2h-SI = serum insulin concentration 120 minutes 
following OGTT in µU.ml-1, 90min-PG = plasma glucose concentration 90 minutes following OGTT 
in mmol.l-1, BW = body weight in kg, AUC-Glu = area under the curve for glucose following OGTT 
in mmol.l-1.2h, GURINE = urinary glucose concentration in mmol.l-1, AUC-Ins = area under the curve 
for insulin following OGTT in µU.ml-1.2h, 2h-PG = plasma glucose 2 h following OGTT in mg.dl-1. 
( )
( ) MPGMSIlog120
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2.4.2 Nonsteady state tracer kinetics 
 
Raw glucose enrichment data were corrected for background enrichment and converted to 
molecule percent excess (MPE) values, then entered into Steel’s model for single-pool nonsteady state 
tracer kinetics for the calculation of rate of plasma glucose appearance (RaTOTAL) and rate of plasma 
glucose disappearance (Rd) [315,316]: 
    
 [2.7] 
 
 
                                         [2.8] 
Where F is the tracer infusion rate in µmol.min-1 corrected for tracer purity (99.0%), pV is the 
volume of distribution in 160 ml.kg-1, C1 and C2 are the plasma glucose concentrations at time 1 and 2 
in mmol.l-1, t1 and t2 are times at time points 1 and 2 in minutes, and E1 and E2 are the plasma [6,6-
2H2]glucose tracer enrichments at time 1 and 2. RaTOTAL and Rd were converted to g.min-1 for graphical 
representation (= µmol.kg-1.min-1 x kg x 180.2 x 10-6). 
 
Rate of endogenous (RaENDO) and exogenous (RaGUT) glucose appearance into the plasma was 
calculated according to Jeukendrup et al (1999) [317] adapted from Steele et al (1968) [318]: 
 
                           [2.9] 
 
                                            
                                                        [2.10] 
 
Where E1 and E2 are the plasma [U-13C]glucose tracer enrichment at times 1 and 2, C1 and C2 
are the plasma glucose concentrations at time 1 and 2 in mmol.l-1, pV is the volume of distribution in 
0.160 l.kg-1, and EOGTT is the [U-13C]glucose tracer enrichment of the oral glucose bolus (again this 
was corrected for tracer purity: 99.0%). RaGUT and RaENDO were converted to g.min-1 for graphical 
representation (= µmol.kg-1.min-1 x kg x 180.2 x 10-6). 
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3. Reliability of the oral glucose tolerance test 
__________________________________________________ 
 
Co-authors: John Ayuk, Andrew A. Toogood, Andrew K. Blannin, Asker E. Jeukendrup 
 
3.1 Abstract 
 
The gold standard glycaemic clamp methodology is not available to every 
laboratory group particularly in non-clinical environments. Oral glucose tolerance 
test-derived estimates of insulin sensitivity have been developed by several research 
groups and have been validated against the glycaemic clamp method. Yet the 
reliability of these estimates in repeated measures is not known. This study assessed 
the reliability of the OGTT in three repeats undertaken by seven male volunteers 
(age 26 ± 2 years, body mass 74.1 ± 2.4 kg, BMI 23.8 ± 0.6 kg.m-2 (mean ± S.E.M.)) 
following strict pre-test diet and exercise controls. Reliability of fasting glucose and 
insulin levels, 2 hour glucose and insulin levels, area under the glucose and insulin 
curves, and various OGTT-derived insulin sensitivity estimates were assessed. The 
reliability of such measures was quite variable with within-subject coefficients of 
variation (typical error) ranging from 5.60 to 48.2% for ISIOGTTMatsuda and 2h-SI  
respectively, and intraclass correlation coefficients (ICC) ranging from R = 0.180 to 
0.981 for 2h-PG and FSI respectively. However, the reliability of the OGTT-derived 
insulin sensitivity index from Matsuda et al (1999) was high, with a typical error of 
5.6% (95% confidence limits, 3.30 to 8.62%), plus an ICC of R = 0.919 (95% 
confidence limits, 0.545 to 0.988). We conclude that if pre-test diet and physical 
activity guidelines are adhered to, then some estimates of ISI derived from the 
OGTT are reliable. 
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3.2 Introduction 
Insulin resistance is the underlying pathology of the metabolic syndrome and diabetes [3,319], 
increasing the risk of cardiovascular disease [15-17,26,27]. Therefore a reliable, valid and efficient 
method of measuring insulin sensitivity is crucial to facilitate early diagnosis and treatment of affected 
or “at risk” individuals. The glycaemic clamp technique is the reference method that gives an estimate 
of peripheral insulin sensitivity by directly measuring the effects of insulin on glucose utilisation under 
steady state conditions [211]. However it is not representative of free-living physiology, and not 
routinely available outside clinical environments. The oral glucose tolerance test (OGTT) is the most 
commonly performed test to measure glucose tolerance, and, with insulin measurements, gives a cheap 
and simple estimate of whole body insulin sensitivity in response to a physiological orally-ingested 
bolus more representative of free-living physiology than the clamp methodology [320]. The OGTT 
also stimulates gastrointestinal peptide pathways such as ghrelin and PYY3-36 which control or 
influence insulin release and glucose kinetics [229,230,321-323], and therefore indices derived from 
OGTT data may yield more physiological (meal-related) information. Clinically, fasting plasma 
glucose (FPG) and two hour post-OGTT plasma glucose (2h-PG) are used as diagnostic tools, yet 
evidence suggests discrepancies exist between FPG and 2h-PG within varying states of glucose 
tolerance [324,325], and poor reliability (i.e. poor consistency of repeated measures) of such measures 
is also reported [224,231-234]. Whilst several groups have presented insulin sensitivity indices (ISI) 
from OGTT-derived data and validated them against gold standard methodology, the reliability of 
these values, which is critical to the valid use of the OGTT in clinical or research environments, has 
not been assessed [219-221]. Our research group wishes to use the OGTT as a tool to assess insulin 
sensitivity during nutritional interventions due to its simple application, gut-dependent nature, 
physiological set-up, and due to the lack of regular access to clinical support for the clamp procedure. 
The aim of this study was to investigate the reliability of several OGTT-derived ISI estimates. 
 
3.3 Methods and materials 
 
Seven lean male volunteers aged 26 ± 2 years, body mass 74.1 ± 2.4 kg, with BMI of 23.8 ± 0.6 
kg.m-2 (mean ± S.E.M.) were recruited from the local community. All volunteers were deemed healthy 
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as assessed by a general health questionnaire and their informed written consent was given prior to 
commencement of the study. Each volunteer underwent OGTTs on three separate occasions over the 
study period. Each trial was separated by at least five days and dietary record was taken for the two 
days preceding the first trial to be matched prior to subsequent visits. Subjects were also instructed to 
refrain from consuming alcohol or caffeine, and from undertaking any non-prescribed exercise for 
forty-eight hours prior to testing. The protocol was approved by the South Birmingham Health 
Authority Local Research Ethics Committee. 
 
3.3.1 The Oral Glucose Tolerance Test (OGTT) 
 
Volunteers arrived in the laboratory at 0800 hours following a 12 hour overnight fast, and were 
studied in a reclined position. An intravenous cannula (BD Venflon, BD, UK) was inserted into an 
antecubital vein and a fasting blood sample was taken. At t = 0 min participants were instructed to 
ingest a 300 ml solution containing 75 g of anhydrous D-glucose (Sigma, UK). Blood samples were 
collected every 15 min until t = 120 min for the determination of glucose and insulin concentrations. 
Blood samples were collected, processed and stored as described in the General Methods section. 
Previously derived insulin sensitivity indices based on frequently-sampled OGTT data (Matsuda et al 
(1999), Stumvoll et al (2000), Soonthornpun et al (2003), Cederholm et al (1990), and Belfiore et al 
(1998) [219-223]) were applied to our data and calculated as described in Section 2.4.1 of the General 
Methods. 
 
3.3.2 Statistical Analysis 
 
Glucose and insulin data were tested for normality and their profiles with time were analysed by 
two-way (trial*time) ANOVA. Reliability of each OGTT-derived ISI plus fasting and 2 hour glucose 
and insulin, and area under the curve (AUC) glucose and insulin values, were assessed using retest 
reliability measures as described by Hopkins et al (2000) [326]. Area under the curve was calculated 
according to the trapezoidal rule. The typical error and the intraclass correlation coefficient (ICC) were 
calculated for each measure derived from the three OGTT retests in each subject. The typical error is 
calculated as the within-subject standard deviation for each measure derived from OGTT repeats (i.e. 
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the random variation in a subject’s value between tests), expressed as the percentage coefficient of 
variation (CV) of the measurement. The ICC is similar to Pearson’s correlation coefficient (r) but 
takes into account the typical error of measurement when more than two repeats have been 
undertaken. The ICC estimates the level of association between the repeated measures and illustrates 
the consistency of the rank order of subject’s scores on retest [327]. To determine the overall 
reliability based on these two statistical values, a rank was assigned to each of the OGTT-derived 
measures, and the measure with the lowest sum of ranks score was chosen as the most reliable 
estimate of insulin sensitivity. 95% confidence limits (95%-CL) were also calculated for these 
reliability estimates. 
 
3.4 Results 
Figures 3.1 and 3.2 illustrate the changes in glucose and insulin concentrations following 
OGTT. Each value in each trial (or OGTT repeat) is expressed as mean ± S.E.M. for n = 7. No 
differences between trials were found (P>0.05). 
 
Figure 3.1 – Plasma glucose concentration profiles following OGTT 
The three trials represent the 75 g OGTT retests that were performed following an overnight 
fast, each separated by at least 5 days. Analysis revealed no significant differences between trials 
(P>0.05). 
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Figure 3.2 – Serum insulin concentration profiles following OGTT 
The legend for the trials is the same as Figure 3.1. Analysis revealed no significant differences 
between trials (P>0.05). 
 
Tables 3.1 and 3.2 illustrate the reliability estimates calculated for each OGTT-derived measure. 
The typical error (expressed as a percentage CV) is listed in ascending order, whilst the ICCs are listed 
in descending order. The insulin sensitivity index from Matsuda et al (1999) (ISIOGTTMatsuda) showed 
the lowest typical error (Table 3.1) between measurements (CV = 5.60%; 95%-CL 3.30 to 8.62%), 
whilst 2h-SI showed the largest (CV = 48.2%; 95%-CL 34.6 to 79.0%). Fasting serum insulin (FSI) 
measures revealed the greatest correlation (Table 3.2) between trials (R = 0.981; 95%-CL 0.876 to 
0.997), and 2 hour plasma glucose (2h-PG) had the poorest correlation (R = 0.180; 95%-CL -0.509 to 
0.753). ISIOGTTMatsuda had the lowest sum of ranks score (= 4), whilst 2h-PG had the largest (= 20). 
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Table 3.1 – Typical error of each OGTT-derived measure 
Three 75 g OGTT retests were performed following an overnight fast, each separated by at least 
5 days. The within-subject standard deviation (typical error) for each measure was calculated and 
expressed as a percentage coefficient of variation. These are listed in order of rank. AUC Glu = area 
under the glucose curve in mmol.l-1.2h; AUC Ins = area under the insulin curve in µU.ml-1.2h; FPG = 
fasting plasma glucose in mmol.l-1; FSI = fasting serum insulin in µU.ml-1; 2h-PG = 2 hour plasma 
glucose in mmol.l-1; 2h-SI = 2 hour serum insulin in µU.ml-1; and ISIOGTT = insulin sensitivity index 
derived from OGTT, the superscript names depict the various ISIs that were calculated.  
 
 
Table 3.2 – The intraclass correlation coefficient between the three OGTT retrials for each measure 
The measures follow the same legend as Table 3.1, and again are listed in order of rank. 
 
 
Measure Typical Error 95% Confidence Limits Rank
(CV, %) Lower Upper
ISIOGTT
Matsuda 5.60 3.30 8.62 1
FSI 8.33 6.23 12.6 2
ISIOGTT
Stumvoll 8.36 6.25 12.6 3
AUC Ins 8.39 6.27 12.6 4
ISIOGTT
Soonthornpun 9.14 6.83 13.8 5
FPG 10.1 7.55 15.3 6
ISIOGTT
Cederholm 10.3 7.68 15.6 7
AUC Glu 12.5 9.31 19.0 8
2h-PG 14.0 10.4 21.4 9
ISIOGTT
Belfiore 17.6 13.1 27.2 10
2h-SI 48.2 34.6 79.0 11
Measure ICC 95% Confidence Limits Rank
Lower Upper
FSI 0.981 0.876 0.997 1
ISIOGTT
Soonthornpun 0.959 0.758 0.994 2
ISIOGTT
Matsuda 0.919 0.545 0.988 3
ISIOGTT
Stumvoll 0.887 0.427 0.983 4
AUC Ins 0.868 0.426 0.979 5
ISIOGTT
Belfiore 0.820 0.187 0.972 6
ISIOGTT
Cederholm 0.802 0.129 0.969 7
2h-SI 0.692 0.010 0.946 8
FPG 0.278 -0.598 0.852 9
AUC Glu 0.229 -0.618 0.831 10
2h-PG 0.180 -0.509 0.753 11
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3.5 Discussion 
 
This study illustrates that the reliability of OGTT-derived measures can be quite variable 
depending on which one is chosen, with CVs ranging from 5.60 to 48.2% and correlation coefficients 
ranging from 0.180 to 0.981. However, the reliability of several of these measures, particularly the 
OGTT-derived insulin sensitivity indices (ISIOGTT), is high, with indices calculated according to 
Matsuda, Stumvoll and Soonthornpun showing typical errors of 5.60, 8.36 and 9.14%, plus correlation 
coefficients of 0.919, 0.887 and 0.959, illustrating the consistency of the rank order of subject’s scores 
between OGTT retests. It also appears that single glucose and insulin concentrations such as FPG, 2h-
PG and 2h-SI are less reliable indices of glucose tolerance or insulin sensitivity. 
 
In a clinical environment the OGTT 2h-PG is used as a second line test to FPG in the diagnosis 
of impaired glucose tolerance (IGT) and diabetes mellitus [320]. Whilst diagnostic sensitivity (i.e. the 
percentage of diabetics identified as positive for diabetes using the OGTT) is high, and prognosis is 
good if disease is detected in its early stages and appropriate treatment is administered, the scientific 
literature and medical opinion questions the reliability of such OGTT measures (FPG and 2h-PG) 
[224,231-234,328,329]. However the poor reliability of such measures in these studies is likely 
attributed to poor pre-test control. Dietary replication and physical activity restriction are imperative 
for consistency of any meal-ingestion protocol. Studies have shown caloric restriction and physical 
activity to upregulate glucose uptake mechanisms almost immediately with lasting effects [330,331]. 
Such controls are not always undertaken in the literature, and particularly in its clinical application the 
recommendation of an unrestricted diet containing more than 150 g.day-1 of carbohydrate for three 
days prior to the OGTT is perhaps ignored by the patient or even not recommended in the first place 
[320]. These dietary guidelines seem quite specific, yet with respect to exercise the only 
recommendation prior to the OGTT protocol is that “the usual physical activity should be undertaken” 
[320]. These activity guidelines are too vague for a variable that has a large effect on glucose tolerance 
and insulin sensitivity. In this study, improved reliability was likely due to tight control of diet and 
exercise for 2 days before the OGTTs; subjects abstained from alcohol, caffeine and exercise, plus 
replicated their diet during the 2 days before each trial. 
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Each of the OGTT-derived ISI models have been previously validated against the 
hyperinsulinaemic euglycaemic clamp [219-223], and in some cases against hyperglycaemic clamps 
[220], the homeostatic model assessment (HOMA), the quantitative insulin sensitivity check index 
(QUICKI) and other ISIOGTT models [221]. The models used in this study each showed a strong 
correlation with ISICLAMP values in their original papers (ISIOGTTMatsuda, r = 0.73, P<0.01 [219]; 
ISIOGTTSoonthornpun, r = 0.87, P<0.01 [221]; ISIOGTTStumvoll, r = 0.79, P<0.01 [220]; ISIOGTTCederholm, r = 
0.53, P<0.01 [222]; ISIOGTTBelfiore, r = 0.64, P<0.01 [223]), validating their use as tools to measure 
insulin sensitivity; however no previous reliability experiments on these measures have been 
undertaken. Our study demonstrates that all of these indices had good reliability, yet by interpreting 
the retest reliability estimates with their corresponding confidence limits and rank order, it would 
appear that ISIOGTTMatsuda is the most reliable with a typical error of 5.6%, ranked 1st (Table 3.1, 95%-
CL, 3.30 to 8.62%), and an ICC of 0.919, ranked 3rd (Table 3.2, 95%-CL, 0.545 to 0.988), giving it 
the lowest sum of ranks score of all our measures. These findings along with data from Matsuda et al 
(1999), which showed a correlation coefficient of 0.73 with clamp-derived ISI estimates [219], 
illustrate the reliability and validity of ISIOGTTMatsuda for use in future research interventions. In 
addition, this is the sole index to have been validated in a cohort exhibiting a range of insulin sensitive 
states (normoglycaemic, impaired glycaemic and diabetes) [219]. Therefore, ISIOGTTMatsuda was chosen 
for future intervention studies in our laboratory. 
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4. The use of isotopic tracers in oral glucose tolerance tests 
__________________________________________________ 
 
Co-authors: John Ayuk, Andrew K. Blannin, Andrew A. Toogood, Asker E. Jeukendrup 
 
4.1 Abstract 
 
The OGTT is a useful physiological test that determines glucose tolerance. 
Changes in postprandial glucose and insulin reflect systemic insulin sensitivity. The 
usefulness of the OGTT in whole-body insulin sensitivity estimation is limited by 
the fact that the contribution of endogenous glucose production or gastrointestinal 
glucose absorption to total glucose appearance cannot be determined. In this study 
four lean male subjects (aged 26 ± 1 years, body mass 73.0 ± 3.9 kg, BMI 23.6 ± 0.9 
kg.m-2 (mean ± S.E.M.) underwent a 75 g OGTT combined with a primed 
intravenous infusion of a [6,6-2H2]glucose tracer and the ingestion of a [U-
13C]glucose tracer. Tracer enrichments were determined by GC-MS and applied to 
Steele’s single pool model of nonsteady state tracer kinetics. Results indicate that 
peak glucose concentrations (8.40 ± 1.08 mmol.l-1) were reached 30 mins after 
glucose ingestion. In addition, endogenous glucose production was suppressed by 
63.8 ± 3.60% from 0.194 ± 0.012 to 0.070 ± 0.007 g.min-1 during the postprandial 
period. This dual-tracer OGTT tool may be used to assess exogenous glucose 
appearance and defects in the insulin-responsiveness of endogenous glucose 
production.  
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4.2 Introduction 
 
The glycaemic clamp is the gold standard technique for measuring insulin sensitivity [211], yet 
the oral glucose tolerance test (OGTT) is the preferred method for diabetes diagnostics that gives 
useful information about glucose tolerance [320]. The OGTT is a physiological test where glucose 
appearance in the blood is dependent on gastric emptying, intestinal absorption and liver function, and 
thus it is more representative of free-living situations (meal ingestion) than infusion-based 
methodology such as the clamp. However, the OGTT, in its simplicity, is also very limited in the 
information it provides. The changes in glucose concentrations that follow are the result of glucose 
fluxes into and out of the plasma compartment; a rise in plasma glucose concentration could be the 
result of reduced tissue glucose uptake, increased hepatic output, or increased intestinal absorption, 
thus the OGTT provides a whole body measure of glucose tolerance. The application of isotopic 
tracers to an OGTT allows quantification of flux into and out of such compartments, providing useful 
information about the existing state of glucose tolerance with regards to the rate of glucose appearance 
and disappearance [332]. In the 1950s and 1960s Steele et al pioneered dual tracer application to 
metabolism calculating tracer kinetics based on a single-pool model [315,318,333]. Since, several 
research groups have attempted to further their work, investigating postprandial glucose metabolism 
during OGTT-type protocols [334,335]. However there is little uniformity in the study designs. This 
study uses a single-pool dual tracer approach to assess whether it is possible to quantify the rate of 
glucose appearance from the gut and from endogenous (hepatic) sources, as well as the rate of glucose 
disappearance from the plasma pool during an OGTT. This is the first study to do so during a standard 
2 hour 75 g OGTT. 
 
4.3 Methods and materials 
 
Subjects. Four habitually active male volunteers aged 26 ± 1 years, body mass 73.0 ± 3.9 kg, 
with BMI of 23.6 ± 0.9 kg.m-2 (mean ± S.E.M.) were recruited from the local community. All 
volunteers were deemed healthy as assessed by a general health questionnaire and provided their 
informed written consent prior to the study. Volunteers underwent an oral glucose tolerance test 
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(OGTT) performed with the use of two stable isotopic derivatives of glucose, and were instructed to 
refrain from consuming alcohol or caffeine and from undertaking any non-prescribed exercise for 
forty-eight hours prior to testing. The protocol was approved by the South Birmingham Health 
Authority Local Research Ethics Committee. 
Protocol. A [6,6-2H2]glucose infusate was prepared the night before each study visit. A known 
trace amount (90 mg.ml-1) of pyrogen-free, 99% purity [6,6-2H2]glucose (Cambridge Isotope 
Laboratories, MA) was dissolved in isotonic saline in a sterile environment. The infusate was 
autoclaved at 120 oC under high pressure and allowed to cool prior to infusion. A 0.2 µm filter was 
placed in the infusion line for the intravenous infusions. Volunteers arrived in the laboratory at 0800 
hours following a 12 hour overnight fast, and were studied in a reclined position. An intravenous 
cannula (BD Venflon, BD, UK) was inserted into an antecubital vein on both arms and a 15 µmol.kg-1 
[6,6-2H2]glucose prime was administered (t = -60 min) into one of the lines immediately followed by a 
constant 0.35 µmol.kg-1.min-1 infusion of [6,6-2H2]glucose for 3 hours via a calibrated infusion pump. 
Infusion rates and primes were based on previous literature and pilot experiments designed to yield an 
optimum enrichment [317,336]. At t = 0 min participants ingested a 300 ml solution containing 73 g of 
anhydrous D-glucose (Sigma, UK) and 2 g of [U-13C]glucose (Isotec Inc, US). Blood samples were 
collected at t = -60 min and every 5 mins during the OGTT period for the measurement of glucose 
concentrations. Glucose tracer enrichments (both [6,6-2H2]- and [U-13C]glucose) were also analysed in 
plasma samples, infusates, and oral glucose boluses. Tracer kinetics were calculated according to 
Steele’s single-pool, non steady-state model [332,333]. Full details of the assays and calculations of 
tracer kinetics are specified in the General Methods chapter.  
 
4.4 Results 
 
Figure 4.1 illustrates the plasma glucose kinetics during OGTT showing the mean ± S.E.M. for 
the four subjects. Peak plasma glucose concentrations (8.40 ± 1.08 mmol.l-1) were reached at t = 30 
mins. [6,6-2H2]glucose enrichment decreased with time whilst [U-13C]glucose enrichment increased 
with time following oral glucose ingestion. Rate of appearance of glucose from the gut (RaGUT) 
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demonstrated increasing contribution to total rate of glucose appearance (RaTOTAL) with time, peaking 
at t = 80 mins (0.352 ± 0.012 g.min-1), whilst the rate of glucose appearance from endogenous sources 
(RaENDO) decreased following glucose ingestion from a basal value of 0.194 ± 0.012 g.min-1. Peak 
suppression of endogenous glucose production was reached at t = 105 mins, when RaENDO = 0.070 ± 
0.007 g.min-1. Rate of glucose disappearance increased with time until t = 70 mins (0.456 ± 0.014 
g.min-1). 
Figure 4.1 – Plasma glucose kinetics during OGTT 
Data represents mean ± S.E.M. A primed 0.35 µmol.kg-1.min-1 intravenous infusion of [6,6-
2H2]glucose began at t = -60 mins. At t = 0 min a 75 g glucose bolus containing 2 g of [U-13C]glucose 
was consumed. Panel (i) shows changes in plasma glucose concentrations with time; panel (ii) shows 
the percentage enrichment of the two tracers in the plasma; panel (iii) shows the rate of glucose 
appearance into the blood pool from exogenous and endogenous sources; and panel (iv) shows the rate 
of glucose disappearance from the blood pool. 
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4.5 Discussion 
 
This data demonstrates that the contribution of endogenous glucose production (RaENDO) to total 
rate of appearance is suppressed by 63.8 ± 3.60% from 0.194 ± 0.012 to 0.070 ± 0.007 g.min-1 
following oral glucose ingestion, and that the rate of glucose appearance from the gut contributed 63.7 
± 5.4% of total glucose appearance during a 2 hour OGTT in lean healthy individuals (mean RaTOTAL 
for the 2 h period = 0.336 ± 0.018 g.min-1, mean RaGUT for the 2 h period = 0.214 ± 0.026 g.min-1). In 
addition, maximal contribution from the gut was 0.352 ± 0.012 g.min-1. This occurred 80 mins 
following ingestion of the OGTT. 
The ability to quantify endogenous glucose production is important for clinical research. 
Elevated hepatic glucose output in the basal and postprandial state is a key aspect of hyperglycaemia 
and insulin resistance, and information regarding the liver’s response to lifestyle or pharmaceutical 
interventions is valuable to clinicians and pharmaceutical companies. Tracer-derived estimates from 
the gold standard clamp technique enables quantification of such variables. However prolonged 
elevation of insulin during such protocols is not representative of free living situations, and therefore 
the OGTT is a useful tool to derive such estimates in a physiological postprandial period. 
Dual tracer methodology to study glucose kinetics during the OGTT was pioneered by Steele et 
al (1956, 1959, 1968) [315,318,333]. Since, several groups have used dual tracer methods to study 
glucose metabolism in the postprandial period, these publications are reviewed in Livesey et al (1998) 
and Basu et al (2003) [334,335]. Within this literature (references [334,337-349]) there is great 
variation in the oral glucose loads, sampling frequencies (> every 15 mins) and sampling durations (< 
8 hours). In addition, different data sets have been analysed using different compartment models 
(single versus multiple) and various volumes of plasma glucose distribution. Despite the non-
uniformity in methodology, all of these publications have quantified RaTOTAL and RaENDO indicating 
that basal endogenous glucose production is approximately 0.175 g.min-1 (2.5 mg.kg-1.min-1) in 
normoglycaemic individuals, and that maximal RaGUT is approximately 0.350 g.min-1 (5.0 mg.kg-1.min-
1) when a 75 g bolus of glucose is ingested. These values are comparable to those found in the current 
study: basal RaENDO = 0.194 ± 0.012 g.min-1 (2.7 mg.kg-1.min-1), maximal RaGUT = 0.352 ± 0.012 g.min-
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1 (5.0 mg.kg-1.min-1). This suggests that our tool may provide reliable information regarding the rate of 
glucose appearance following OGTT. However, recent literature from Basu et al (2003) and Toffolo et 
al (2006) published after we had completed the current study, suggest that errors in RaENDO 
measurements may arise from rapid changes in postprandial glucose enrichment when using a dual-
tracer nonsteady state single-pool methodology [335,350]. These groups have suggested that triple-
tracer multiple-pool modelling using variable tracer infusion rates provide better estimates of glucose 
rates of appearance. However, the complexity of such studies seems to prevent its routine use in 
clinical studies evaluating the effect of therapeutic interventions.   
In addition to Steele’s single-pool model used in this and other studies [333], alternative 
multiple-pool models exist to better estimate glucose kinetics within plasma and interstitial fluid 
compartments (e.g. Radziuk et al 1978 [351], or Mari et al 1994 [346]). In addition, several studies 
have used different values to represent the plasma glucose space. The effectiveness of the Steele 
equation to accurately calculate Ra may depend on the value of the glucose space [332,352,353]. One 
of the most recent studies to apply dual stable isotope tracer methodology to the OGTT is that of 
Livesey et al (1998) [334]. This publication performed analysis of dual-tracer OGTT data using a 
single- (e.g. Steele et al 1959 [333]) and a two-pool (Mari et al 1994 [346]) model of glucose kinetics 
with different values for the glucose space. Interestingly, they demonstrated that the model and 
glucose distribution values have very little effect upon calculated Ra values [334]. The size of the pool 
(0.160 l.kg-1) used in our analysis was based on recent stable isotope dual-tracer literature (e.g. 
Jeukendrup et al 1999 [317], Delarue et al 1996 [349]), however other literature using radioactive 
dual-tracer methods have used pool sizes ranging from 0.095 to 0.230 l.kg-1. When we apply these 
ranges to our analysis, it actually makes very little difference to the resultant Ra values. For example, 
when analysing our data with glucose pool sizes of 0.095 and 0.230 l.kg-1, the resultant basal RaENDO 
values were 0.194 and 0.194 g.min-1 respectively, and maximal RaGUT values were 0.352 and 0.353 
g.min-1, respectively. Therefore the size of the glucose space appears to have little effect on the 
calculated rates of glucose appearance.  
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This study improves on previous work as stable isotopes, although more expensive, are safer 
and more ethical than using radioactive moieties which are employed in the majority of tracer studies 
[332]. Also, by using solely stable isotopes rather than a mixture of radioactive and stable isotopes like 
several previous publications (e.g. [338,347,354,355]), data analysis will be more rapid. Additionally, 
our sampling frequency of 5 min is of higher resolution than the 10-30 min frequency used in previous 
work. This minimises large fluctuations in tracer enrichment between consecutive samples thus 
minimising variation in Ra during nonsteady-state glucose flux [332]. In addition, unlike the majority 
of previous publications [339-348], including the dual tracer stable isotope work by Delarue et al 
(1996) [349] and Livesey et al (1998) [334], our protocol replicates the standard 2 hour 75 g OGTT 
used in clinical practice [320], thus illustrating that detection of changes in rate of glucose appearance 
is possible during a relatively short patient intervention. This current study has however only been 
undertaken in a relatively small, healthy cohort, and so future work should focus on applying such a 
tool to individuals with a large range of insulin sensitivity. Additionally, by measuring insulin 
concentrations, it would be useful to develop an insulin sensitivity index from our OGTT-derived 
RaENDO measure (rate of glucose appearance from the liver per unit of insulin) and validate it against 
RaENDO data from glycaemic clamp methodology. 
In conclusion, this study illustrates that estimates of the rate of glucose appearance from 
endogenous and exogenous sources can be quantified during 2 hour 75 g OGTT protocols using safe 
stable isotope glucose tracers. These findings indicate that, if applied to an insulin resistance group, 
valuable information regarding hepatic glucose production may be obtained. Such information would 
be of use in research to detect specific metabolic abnormalities (e.g. hepatic insulin resistance) and 
thus find the most effective therapeutic intervention. However, with recent work from Basu et al 
(2003) indicating the uncertainty of single-pool, nonsteady state dual-tracer data, further work is 
required to determine its reliability and its capacity to measure changes in insulin sensitivity in 
response to therapeutic interventions in patients with insulin resistance. 
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5. Effects of acute cinnamon ingestion on insulin sensitivity 
__________________________________________________ 
 
Co-authors: Andrew K. Blannin 
Publication status: In press in Diabetes Obesity and Metabolism 
 
5.1 Abstract 
 
Cinnamon spice and its phenolic extracts have been demonstrated to exhibit 
insulin-like actions in vitro. In humans the evidence surrounding cinnamon-induced 
improvements in glycaemia and insulin sensitivity is controversial. In this study, 
seven sedentary but otherwise healthy male volunteers (aged 26 ± 1 years, body 
mass 77.0 ± 1.6 kg, and BMI 24.5 ± 0.3 kg.m-2) underwent three oral glucose 
tolerance tests (OGTT). One trial involved consuming a 5 g placebo with the OGTT 
(OGTTcontrol), another required the ingestion of 5 g of cinnamon with the OGTT 
(OGTTcin), and the other trial involved consuming 5 g of cinnamon 12 hours before 
the OGTT (OGTTcin12hpre). This study demonstrates that cinnamon ingestion reduces 
the total plasma glucose response to oral glucose ingestion (measured as area under 
the curve for 2 hours after ingestion) by -12.9 ± 4.2% and -10.0 ± 3.7% for OGTTcin 
(P<0.05) and OGTTcin12hpre (P<0.05) respectively compared with OGTTcontrol. 
Cinnamon also improved insulin sensitivity as assessed by Matsuda et al (1999) in 
both OGTTcin (P<0.05) and OGTTcin12hpre (P<0.05) trials compared with OGTTcontrol. 
This current study is the first to illustrate that acute cinnamon spice supplementation 
can improve in vivo insulin sensitivity in humans, and that not only are its effects 
immediate, they also appear to be sustained for 12 hours. 
 
 48
5.2 Introduction 
 
Insulin resistance is the underlying pathology of T2DM and the metabolic syndrome [3]. Insulin 
sensitivity is easily measured and changes over time can be accurately monitored [185]. Large 
improvements in insulin sensitivity and other factors associated with the metabolic syndrome are seen 
following lifestyle or pharmaceutical intervention [191,200] yet prevalence rates continue to escalate 
[2] and therefore a search for alternative targets or therapeutics is sensible. Cinnamon spice appears to 
have insulin mimetic properties [235,237]; cinnamon extracts have been shown to increase in vitro 
adipocyte glucose uptake [236,356], and in vivo animal studies have demonstrated increased glucose 
utilisation and upregulation of insulin signalling events, such as increased phosphorylation of the 
insulin receptor and insulin receptor substrates (IRS-1) [243,244]. However, in vivo human evidence is 
mixed and somewhat limited. Currently there are three published studies in humans. Khan et al (2003) 
demonstrated reduced fasting glucose and lipids (by 18-29%) in T2DM patients following 40 days of 
1, 3, or 6 g.day-1 Cinnamomum cassia feeding [238]; Mang et al (2006) showed that 3 g.day-1 reduced 
fasting glucose (by 10%) in T2DM patients after 4 months [239]; yet Vanschoonbeek et al (2006) 
failed to show any effect of a 6 week 1.5 g.day-1 feeding regime on fasting measures or insulin 
sensitivity in postmenopausal T2DM volunteers [240]. At the time of commencing this study, the 
paper by Khan et al (2003) was the only available publication. Their data investigated the effects of 
cinnamon ingestion on fasting plasma glucose (FPG) but no data were presented on insulinaemia or 
insulin sensitivity [238]. Also, despite evidence of an effect on FPG it was not known if this was due 
to the final dose of cinnamon taken 12 hours before the blood sample or an accumulative effect of 40 
days cinnamon ingestion [238]. Therefore this study investigated the acute effects of a single 
cinnamon bolus upon an oral glucose tolerance test (OGTT)-derived insulin sensitivity estimate.  
 
5.3 Methods and materials 
Following ethical approval from The School of Sport and Exercise Sciences Safety and Ethics 
Subcommittee, seven sedentary but otherwise healthy male volunteers, aged 26 ± 1 years, body mass 
77.0 ± 1.6 kg, and BMI 24.5 ± 0.3 kg.m-2, were recruited from the local community. All volunteers 
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were assessed by a general health questionnaire and provided informed written consent prior to 
commencing the study. Participants made a total of three visits to the laboratory each separated by at 
least five days. A dietary record was taken for the two days preceding the first test, and subjects were 
instructed to refrain from consuming alcohol, caffeine, and cinnamon products, and from any 
exercise for forty-eight hours prior to each trial. The dietary record was for the purposes of diet 
replication prior to each trial. Trials were assigned in a single-blind randomised cross-over design: a 
placebo-controlled oral glucose tolerance test (OGTTcontrol), an OGTT supplemented with cinnamon 
(OGTTcin), and an OGTT with cinnamon ingested twelve hours prior to the trial (OGTTcin12hpre).  A 12 
h delay between cinnamon ingestion and OGTT was chosen to replicate the delay between final 
dosing and blood sampling in Khan’s publication [238]. Because two trials involved consuming 
capsules with the OGTT and the other trial involved consuming capsules the night before, the 
subjects could have been aware of the trial allocation.  Therefore, dummy capsules containing 
placebo were consumed at appropriate times to ensure the same number of capsules were consumed 
12 hours before and with each OGTT for each trial to preserve blinding. In addition, to test the effects 
our chosen placebo may have on glucose clearance, four subjects volunteered to undergo two further 
OGTTs with and without 5 g of placebo capsules. 
 
5.3.1 OGTTcontrol 
Subjects arrived in the laboratory at 0800 hours following an overnight fast. An intravenous 
cannula (BD Venflon, Oxford, UK) was inserted into an antecubital vein and a fasting blood sample 
was taken. At 0830 hours the OGTT commenced: subjects were instructed to ingest a 75 g bolus of 
dextrose (Cerestar, Manchester, UK) in 300 ml of water. Blood samples (5 ml) were drawn from the 
intravenous line at t = 0, 30, 60, 90, and 120 min following ingestion of the drink. During the trial the 
cannula was kept patent with 5 ml flushes of 0.9% NaCl(aq) saline (Baxter Healthcare, Northampton, 
UK) following each blood-letting. All volunteers were administered 5 g (= 10 x 500 mg capsules) of 
vegi-capsulated wheat flour placebo capsules to consume twelve hours prior to (at 2030 hours the 
previous night following evening meal), and immediately before the OGTT. Wheat flour was chosen 
in accordance with Khan et al (2003) [238]. All blood sample handling, storage, and analysis 
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procedures (for glucose and insulin concentrations) are described in the General Methods section 
(Chapter 2).  
 
5.3.2 OGTTcin 
Subjects followed the same protocol in this trial as for OGTTcontrol, however, 5 g (= 10 x 500 
mg capsules) of vegi-capsulated Cinnamomum cassia spice (Everythingcinnamon.com, Essex, UK) 
was ingested with the oral glucose bolus at t = 0 min. Subjects were also given 5 g of vegi-capsulated 
wheat flour placebo capsules to ingest twelve hours prior to OGTT, i.e. at 2030 hours the previous 
night following all evening meals. The dietary intake diary was followed as described above, and 
blood samples were collected and stored in the same manner. A 5 g cinnamon bolus was chosen 
based on a weighted average of the data from Khan et al (2003) that showed that 6 g had a slightly 
greater effect than 3 g upon FPG [238]; because their data showed doubling the dose did not double 
the effect this indicated higher doses were unlikely to produce effects on a pro rata basis. The data of 
Khan et al (2003) also showed that 1g of cinnamon has little effect on FPG.   
 
5.3.3 OGTTcin12hpre 
 
Again the same protocol was followed as for OGTTcontrol; however subjects were given 5 g of 
vegi-capsulated cinnamon to ingest twelve hours prior to the OGTT, i.e. at 2030 hours the previous 
evening. Also, 5 g of vegi-capsulated wheat flour placebo capsules were ingested with the OGTT at t 
= 0 min. Again dietary intake diaries were followed as described, and blood samples were collected, 
stored, and analysed in the same manner.  
 
5.3.4 Insulin sensitivity measurement 
Several methods to measure insulin sensitivity are available; these are described in the General 
Introduction (Section 1.4). In this study the OGTT was used to investigate changes in insulin 
sensitivity. Estimates derived from OGTT data have been validated elsewhere [219-223] and their 
reliability is assessed in Chapter 3. As described in Chapter 3 ISIOGTTMatsuda was considered to be the 
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most reliable insulin sensitivity index for repeated measures interventions and so was selected for this 
study [219]. Calculations are described in the General Methods section (Equation 2.2).  
 
5.3.5 Statistical Analysis 
Data are expressed as mean ± S.E.M. and statistical analysis was carried out with SPSS for 
Windows 12.0.1 (SPSS Inc, Chicago, US). Raw glucose and insulin data were tested for normality and 
analysed using two-way (time*trial) repeated measures ANOVA. Main effects were analysed using 
Bonferroni post hoc tests. Raw data was converted to area under the curve (AUC) values by the 
trapezoidal method and compared using one-way ANOVA. Significant differences were accepted at 
P<0.05. Based on the effect size found in this study, a power calculation, with power set at 0.8 and 
alpha at 0.05, showed that investigating ten subjects should be sufficient to detect significant 
differences between trials in a future study. 
 
5.4 Results 
Ingestion of wheat flour with an OGTT did not change the glucose response (AUC) to an OGTT 
compared with an OGTT without flour ingestion (Figure 5.1). 
 
Figure 5.1 – Effect of wheat flour placebo on glucose responses following OGTT 
Four subjects volunteered to undergo two further OGTTs with and without 10 x 500 mg (total = 
5 g) wheat flour capsules. No differences were found between trials, P>0.05. Data represents mean ± 
S.E.M. 
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5.4.1 Plasma glucose responses to OGTT in each trial 
 Analysis of raw data showed a main effect of trial with plasma glucose being lower in 
OGTTcin and OGTTcin12hpre trials compared with OGTTcontrol (P<0.05, Figure 5.2). Prior to OGTT, 
fasting plasma glucose measures were taken: 4.89 ± 0.18, 4.75 ± 0.10, and 4.69 ± 0.15 mmol.l-1 for 
OGTTcontrol, cin, and cin12hpre respectively. No significant differences were found in these data (P>0.05). 
Plasma glucose measures at peak (t = 30 mins) and t = 120 mins were also compared, and again no 
statistical differences between trials were found (P>0.05). The area under the plasma glucose curve 
was significantly decreased in OGTTcin and OGTTcin12hpre trials by 12.9 ± 4.2% and 10.0 ± 3.7% 
respectively when compared with OGTTcontrol (P<0.05), but no differences were found between the 
two cinnamon trials (Figure 5.3).  
 
Figure 5.2 – Plasma glucose responses during OGTT 
In each trial a 75 g 300 ml OGTT was ingested. In OGTTcontrol, 5 g of placebo capsules were 
ingested with and 12 h prior to OGTT; In OGTTcin, 5 g of cinnamon was ingested with the OGTT and 
5 g of placebo was ingested 12 h prior; and in OGTTcin12hpre, 5 g of placebo was ingested with the 
OGTT, whilst 5 g of cinnamon was taken 12 h prior. Glucose concentrations at t = 30 mins were 
significantly different from baseline in all trials (**, P<0.01). Glucose responses in OGTTcin and 
OGTTcin12hpre were also significantly different from OGTTcontrol (#, P<0.05) but not from one another 
(P>0.05). Data represents mean ± S.E.M. 
 
 
 
 
 
 
 
2.50
3.50
4.50
5.50
6.50
7.50
8.50
0 30 60 90 120
Time following OGTT (minutes)
G
lu
co
se
 c
on
ce
nt
ra
tio
n 
(m
m
ol
.l-1
)
OGTTcontrol
OGTTcin
OGTTcin12hpre
**
#
#
G
lu
co
se
 c
on
ce
nt
ra
tio
n 
(m
m
ol
.l-1
)
G
lu
co
se
 c
on
ce
nt
ra
tio
n 
(m
m
ol
.l-1
)
 53
Figure 5.3 – Area under the plasma glucose response curve during OGTT 
The three trials follow the same legend as in Figure 5.2. Glucose responses in OGTTcin and 
OGTTcin12hpre were significantly lower than OGTTcontrol (*, P<0.05), though not statistically different 
from one another (P>0.05). Data represents mean ± S.E.M. 
 
5.4.2 Serum insulin responses to OGTT in each trial 
Figure 5.4 demonstrates the serum insulin responses to OGTT during the three trials. No 
differences in insulin responses were found between trials (P>0.05). No significant differences were 
found between trials in fasting serum insulin concentrations (P>0.05), nor were any differences found 
between trials in peak (t = 30 min) or t = 120 min concentrations (P>0.05).  Insulin AUC data was not 
significantly different between trials (Figure 5.5). 
Figure 5.4 – Serum insulin responses during OGTT 
Again, in OGTTcontrol, 5 g of placebo capsules were ingested with and 12 h prior to OGTT; In 
OGTTcin, 5 g of cinnamon was ingested with the OGTT and 5 g of placebo was ingested 12 h prior; 
and in OGTTcin12hpre, 5 g of placebo was ingested with the OGTT, whilst 5 g of cinnamon was taken 12 
h prior. Insulin concentrations at t = 30, 60, and 90 mins were significantly different from baseline in 
all trials (**, P<0.01). Insulin responses were not different between trials (P>0.05). Data represents 
mean ± S.E.M. 
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Figure 5.5 – Area under the serum insulin response curve during OGTT 
The three trials follow the same legend as in Figure 5.4. Insulin responses were not different 
between trials (P>0.05). Data represents mean ± S.E.M. 
 
5.4.3 Changes in insulin sensitivity 
Figure 5.6 illustrates insulin sensitivity data derived from ISIOGTTMatsuda. Insulin sensitivity was 
elevated in both the cinnamon trials compared to OGTTcontrol (P<0.05), though they were not different 
from one another (P>0.05). 
 
Figure 5.6 – Insulin sensitivity assessed by ISIOGTT (Matsuda et al, 1999)  
The three trials follow the same legend as in Figure 5.4. The ISIOGTT index derived from 
Matsuda et al (1999) [219] revealed greater insulin sensitivity in the OGTTcin and cin12hpre trials 
compared to OGTTcontrol (*, P<0.05). Data represents mean ± S.E.M. 
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5.5 Discussion 
 
This study demonstrates that a single bolus ingestion of 5 g of cinnamon spice can reduce blood 
glucose responses to an OGTT and improve insulin sensitivity in inactive but otherwise healthy 
individuals. These data also show that the effects persist for 12 hours following cinnamon ingestion. 
The choice of wheat flour as a placebo was shown to have no effect on glucose responses, nor could 
volunteers distinguish it from the cinnamon capsules.  
 
Elevated fasting and postprandial glycaemia can contribute to the onset of metabolic disease via 
non-enzymatic protein glycation or toxic effects on the vascular endothelium [357,358]. 
Improvements in insulin sensitivity can help to maintain blood glucose homeostasis and prevent the 
detrimental effects of hyperglycaemia [200]. In 1990 it was first described that cinnamon may enhance 
in vitro glucose utilisation in rat adipocytes [235]. Other groups have published data supporting these 
findings with increased glucose uptake and glycogen synthesis in 3T3-L1 cell lines [236,237]. The 
cinnamon-induced lowering of in vivo glucose responses may indeed be explained by reduced gastric 
emptying or delayed intestinal absorption [359]; however, our data show no delay in peak glucose 
concentrations following cinnamon ingestion. In addition, the literature suggests that cinnamon 
extracts can directly upregulate insulin receptor autophosphorylation and inhibit phosphatase action 
and glycogen synthase kinase-3β (GSK-3β) activity in vitro [241]; and recent in vivo evidence in rats 
shows cinnamon-induced increases in skeletal muscle IRS-1 tyrosine phosphorylation and IRS-1-PI3K 
association [244], therefore cinnamon’s effects on insulin sensitivity may act directly on aspects of the 
insulin signalling cascade that are directly associated with insulin resistance and T2DM [71,360,361]. 
Current molecular data however is restricted to animals or in vitro work, therefore extrapolation to 
humans should be treated with caution. 
 
Currently only three publications report cinnamon’s effects on glycaemic control and insulin 
sensitivity in humans [238-240]. Interestingly, Vanschoonbeek et al (2006) failed to show any effect 
of cinnamon ingestion upon OGTT-derived insulin sensitivity estimates [240]. Their study 
investigated postmenopausal T2DM women and employed 1.5 g.day-1 over a 6 week feeding 
intervention [240]. Khan et al (2003) and Mang et al (2006) however have reported that cinnamon 
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ingestion can reduce FPG in T2DM patients following 40 days and 4 months interventions 
respectively [238,239]. These conflicting findings may be attributed to the doses employed. Khan et al 
(2003) found little effect of 1 g.day-1, yet marked effects at 3 and 6 g.day-1, and Mang et al (2006) 
showed an effect using 3 g.day-1. Vanschoonbeek’s study made use of a 1.5 g.day-1 cinnamon 
supplementation, perhaps a level lower than the therapeutic requirement. Khan et al (2003) also 
reported that 20 days following removal of the 40 day cinnamon stimulus, lowered FPG persisted 
[238]. Whilst our study found no effect on FPG measures it did demonstrate a persistent effect on 
insulin sensitivity 12 hours after cinnamon ingestion, suggestive that cinnamon may have prolonged 
effects on events associated with increased insulin sensitivity. It would therefore be sensible to 
investigate the prolonged effects on insulin sensitivity following removal of the cinnamon stimulus. 
However, our data are representative of a lean population and so care must be taken if extrapolating 
these findings to an insulin resistant or obese group.  
 
Differences in findings between groups may also be attributable to the pre-test standardisation. 
The presently available studies all have discrepancy with respect to dietary and physical activity 
control, and to the type of drug the patients were taking. For example, the publications by Mang et al 
and Khan et al fail to describe dietary or exercise control during their interventions. These are factors 
that can markedly influence glycaemic control and insulin sensitivity [200], and so care must be taken 
in comparing such findings. In addition, the data of Mang et al (2006), like that of Khan et al (2003), 
described decreased FPG as a result of cinnamon ingestion but also found a correlation between the 
size of improvement and the pre-intervention FPG [239]. This suggests that improvements in FPG are 
found with higher pre-trial values, i.e. with poorer glycaemic control. The discrepancies between 
studies may therefore become clear by looking at the pre-trial FPG values: Khan et al (2003) – 11.4-
16.7 mmol.l-1; Mang et al (2006) – 9.3 mmol.l-1; Vanschoonbeek et al (2006) – 8.3 mmol.l-1; present 
study – 4.9 mmol.l-1. No changes in FPG were found in our data or Vanschoonbeek’s data, studies 
with the lowest pre-intervention values. 
 
Besides FPG, postprandial glucose and insulin levels are also useful markers of insulin 
sensitivity. The current data adds to the evidence base that cinnamon spice may improve glycaemic 
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control and insulin sensitivity, and that these effects persist for 12 hours; however, in human patient 
groups the evidence is varied. The current data in T2DM illustrates improved fasting glycaemia but no 
effects upon insulin sensitivity, haemoglobin A1c (HbA1c), or HDL cholesterol (HDL-c) [238-240]. 
The literature illustrates that HbA1c and HDL-c are significant markers of glycaemic control and 
cardiovascular risk prognosis [362-364], and therefore with a lack of evidence with regard to long-
term health outcome, further studies are required before cinnamon supplementation can be 
recommended. Given the in vivo animal evidence that cinnamon may upregulate peripheral glucose 
uptake and intracellular insulin signalling mechanisms; it would be sensible to investigate cinnamon 
ingestion on such factors in humans, particularly with regard to myocellular glucose utilisation, the 
major site of insulin-stimulated glucose uptake. 
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6. Effects of long-term cinnamon ingestion on insulin 
sensitivity 
__________________________________________________ 
 
Co-authors: Lisa Fenton, Amanda Tee, Andrew K. Blannin 
 
6.1 Abstract 
 
Cinnamon spice can improve fasting glycaemia in humans yet data on insulin 
sensitivity are limited and controversial. Evidence shows prolonged effects on 
fasting glycaemia following 40 days of cinnamon feeding (Khan et al 2003), and on 
insulin sensitivity 12 hours after a single cinnamon bolus (Chapter 5), but insulin 
sensitivity data following long term cinnamon feeding are less convincing. In this 
study, eight sedentary but otherwise healthy male volunteers (aged 25 ± 1 years, 
body mass 76.5 ± 3.0 kg, BMI 24.0 ± 0.7 kg.m-2; mean ± S.E.M.) underwent two 14 
day interventions involving either cinnamon spice (Cinnamomum cassia) or placebo 
supplementation (3 g.day-1). Placebo supplementation was continued for 5 days 
following this 14 day period. Oral glucose tolerance tests (OGTT) were performed 
on days 0, 1, 14, 16, 18, and 20. Cinnamon ingestion reduced area under the glucose 
curve response to OGTT at day 1 (-13.1 ± 6.3% versus day 0; P<0.05) but this effect 
was lost by day 14 of cinnamon supplementation. Cinnamon ingestion reduced the 
area under the insulin curve response at day 14 (-27.1 ± 6.2% versus day 0; P<0.05), 
as well as improving insulin sensitivity as assessed by ISIOGTTMatsuda at day 14 
(versus day 0; P<0.05). However, these effects were lost during the 5 day period 
following removal of the cinnamon feeding stimulus at day 14. These data add to the 
evidence that cinnamon spice can improve in vivo glycaemic control and insulin 
sensitivity in humans, but that effects on insulin sensitivity are not persistent once a 
prolonged period of cinnamon supplementation is ceased. 
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6.2 Introduction 
 
Clear positive effects of cinnamon extracts and cinnamon spice ingestion on glucose utilisation 
and aspects of insulin signalling have been demonstrated in vitro [236,356] and in vivo in animals 
[244,246], yet the in vivo human evidence is controversial. Khan et al (2003) were the first group to 
demonstrate that 1, 3, and 6 g.day-1 of cinnamon may reduce FPG in T2DM patients [238], a finding 
confirmed with 3 g.day-1 by Mang et al (2006) [239], but opposed with 1.5 g.day-1 by Vanschoonbeek 
et al (2006) [240]. In addition, Khan et al (2003) published evidence that cinnamon ingestion may 
have lasting effects on FPG (and lipids) up to 20 days post-cessation of supplementation [238]. At the 
time of commencing this study, Khan et al (2003) was the only available study, and no evidence of 
long term effects of cinnamon ingestion on insulin sensitivity had been presented in humans. The 
previous chapter presents evidence that an acute 5 g cinnamon bolus can reduce OGTT glucose area 
under the curve (AUC) and improve insulin sensitivity for up to 12 hours post-ingestion, the next step 
was to establish if repeated daily ingestion of cinnamon over many days had an accumulative effect on 
insulin sensitivity. Cinnamon’s therapeutic value would, to some extent, be influenced by the 
preservation of the effect following its withdrawal; therefore we also investigated the time course of 
insulin sensitivity changes after removal of a 2 week cinnamon feeding intervention.  
 
6.3 Methods and materials 
Following ethical approval from The School of Sport and Exercise Sciences Safety and Ethics 
Subcommittee, eight sedentary but otherwise healthy male volunteers, aged 25 ± 1 years, body mass 
76.5 ± 3.0 kg, and BMI 24.0 ± 0.7 kg.m-2 (mean ± S.E.M.), were recruited from the local community. 
All volunteers were assessed by a general health questionnaire and provided informed written consent 
prior to commencing the study. A dietary record was taken for the two days preceding the first test, 
and subjects were instructed to refrain from consuming alcohol, caffeine, and cinnamon products, and 
from any exercise regime during the whole intervention period. The dietary record was for the 
purposes of diet replication prior to each trial. Each subject completed two 20 day interventions in a 
single-blind randomised cross-over design: a control intervention (Control trial) and a cinnamon 
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intervention where cinnamon was consumed during the first 14 days (Cinnamon trial). The 
interventions were as follows and are summarised in Figure 6.1: 
 
Figure 6.1 – Summary of the intervention periods 
 
6.3.1 Control trial 
On day 0, volunteers arrived in the laboratory at 0800 hours following an overnight fast. An 
intravenous cannula (BD Venflon, Oxford, UK) was inserted into an antecubital vein and a fasting 
blood sample was taken. At 0830 hours subjects were instructed to ingest a 75 g bolus of dextrose 
(Cerestar, Manchester, UK) in 300 ml of water (OGTT). Blood samples (3 ml) were drawn from the 
intravenous line at t = 0, 30, 60, 90, and 120 min following ingestion of the drink. During the trial the 
cannula was kept patent with 3 ml flushes of 0.9% NaCl(aq) saline (Baxter Healthcare, Northampton, 
UK) following each blood-letting. Blood samples were collected, stored, and analysed as described in 
the General Methods section. Volunteers returned to the laboratory for further OGTTs at 0800 hours 
on days 1, 14, 16, 18, and 20, having followed their diet diary. In addition, on days 0-14, subjects were 
given vegi-capsulated wheat flour placebo pills each containing 500 mg of wheat flour, and instructed 
OGTTs carried out at Day 0, 1, 14, 16, 18, and 20
Day 
0 1 14 16 18 20 
Control 
Day 
0 1 14 16 18 20 
Cinnamon 
Placebo  Placebo 
CINNAMON Placebo 
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to take 6 pills per day (= 3 g.day-1) at 2030 hours following their evening meal. Further placebo pills 
were given on days 15-19; again 6 pills were taken at 2030 hours each day. 
 
6.3.2 Cinnamon trial 
This period followed exactly the same protocol as the control trial. However, instead of 
administering placebo capsules on days 0-14, subjects were given 500 mg vegi-capsules containing 
cinnamon spice (Cinnamomum cassia). Volunteers were instructed to consume 6 pills (= 3 g) each day 
at 2030 hours, following their evening meal. At day 15 subjects consumed 6 x 500 mg wheat flour 
placebo capsules each evening for the remaining 5 days. OGTTs followed the protocol above and 
blood collection proceeded in the same fashion. The dose in this study was reduced to 3 g from 5 g in 
the previous study due to concerns of compliance and potential gastrointestinal problems of ingesting 
10 x 500 mg pills per day for 2 weeks. Furthermore, given the evidence that at 3 g.day-1 Khan et al 
(2003) demonstrated significant reductions in FPG after 20 days feeding (-13%), 40 days feeding (-
18%), plus a persistent reduction 20 days after ceasing cinnamon supplementation (-13%), it was 
considered likely that 3 g.day-1 would provide an effective stimulus. Measures at day 1 were included 
to confirm the findings from the previous chapter and to enable comparisons to be made between 
single and accumulative effects of cinnamon ingestion (measures on day 1 and day 14 were compared 
with values on day 0 to give acute and chronic effects, respectively). Measures were taken at 2 day 
intervals following removal of the cinnamon stimulus to investigate the time course of post-
intervention recovery. 
 
6.3.3 Insulin sensitivity measurement 
As described in the previous chapter, ISIOGTTMatsuda was considered to be the most reliable index 
for repeated measures interventions and so was selected for this study [219]. Calculations are 
described in the General Methods section (Chapter 2).  
 
 
 
 62
6.3.4 Statistical Analysis 
Data are expressed as mean ± S.E.M. and statistical analysis was carried out with SPSS for 
Windows 12.0.1 (SPSS Inc, Chicago, US). Raw glucose and insulin data were tested for normality and 
analysed by three-way (time*day*intervention) repeated measures ANOVA. Main effects were 
analysed using Bonferroni post hoc tests. Raw glucose and insulin data were converted to area under 
the curve (AUC) values by the trapezoidal method. AUC and insulin sensitivity data were analysed 
using two-way (day*intervention) repeated measures ANOVA, and again any main effects were 
analysed using Bonferroni post hoc procedures. Significance was achieved when P<0.05.  
 
6.4 Results 
6.4.1 Plasma glucose responses to OGTT during each intervention 
Figure 6.2 illustrates the glucose responses following OGTT on each day, and Figure 6.3 
summarises the AUC data. No significant interactions were present in the OGTT raw glucose profile 
data (intervention*time – P=0.10, day*time – P=0.11, intervention*day – P=0.09, and 
intervention*day*time – P=0.13). Statistical analysis of AUC data also failed to show a 
day*intervention interaction (P=0.13), however a separate analysis comparing day 1 of the cinnamon 
trial to day 0 of the cinnamon trial revealed decreased AUC glucose (-13.1 ± 6.3%; Figure 6.3, 
P<0.05). A comparison between day 1 cinnamon and day 1 control revealed a significant difference in 
glucose responses (-13.9 ± 3.9%; P<0.05). Comparing day 14 of the cinnamon trial to day 0 of the 
cinnamon trial showed no change (-5.5 ± 8.1%; P>0.05), and a comparison between day 14 cinnamon 
and day 14 control also showed no changed (-12.3 ± 11.8%; P>0.05). In addition, no significant 
differences were found between trials for fasting or 2 hour OGTT glucose data (P>0.05). 
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Figure 6.2 – Glucose concentration profiles following OGTT during each intervention period 
OGTTs were undertaken at days 0, 1, 14, 16, 18, and 20 during the intervention period. Bold 
lines represent the control trial, where 3 g of placebo was administered each day. Dashed lines 
represent the cinnamon trial, where 3 g of cinnamon spice was administered each day until day 14, 
from when 3 g of placebo where given until the end of the 20 day intervention. The insert graph on 
each day represents total area under the glucose curve (AUC) for each OGTT. Glucose AUC was 
decreased at day 1 in the cinnamon intervention compared to control. * represents significant 
differences at P<0.05. Data represents mean ± S.E.M. 
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Figure 6.3 – Summary of the area under the OGTT glucose curve on each study day 
OGTTs were undertaken at days 0, 1, 14, 16, 18, and 20. CONTROL (white bars) represents 3 g 
of placebo administered each day. CINNAMON (shaded bars) represents 3 g of cinnamon 
administered each day until day 14. Analysis of area under the glucose curve following OGTT 
revealed no intervention*day interaction (P=0.13). However, a separate analysis comparing just Day 1 
to Day 0 did demonstrate reduced area under the curve in the cinnamon trial (* indicates P<0.05). No 
differences within the control trial were found (P>0.05). Data represents mean ± S.E.M. 
 
6.4.2 Serum insulin responses to OGTT during each intervention 
Figures 6.4 and 6.5 illustrate the insulin responses and AUC during OGTT, respectively. No 
significant interactions were present in the OGTT raw insulin profile data (intervention*time – 
P=0.08, day*time – P=0.10, intervention*day – P=0.07, and intervention*day*time – P=0.12). 
Analysis of AUC data revealed a day*intervention interaction (P<0.05), where AUC at day 14 in the 
cinnamon trial was significantly reduced compared to day 0 (-27.1 ± 6.2%; Figure 5.5, P<0.05). AUC 
values at day 14 were also lower in the cinnamon trial than in the control trial (-22.0 ± 10.4%; figure 
6.5, P<0.05). No significant differences were found between trials for fasting or 2 hour OGTT insulin 
data (P>0.05). 
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Figure 6.4 - Insulin concentration profiles following OGTT during each intervention period. 
OGTTs were undertaken at days 0, 1, 14, 16, 18, and 20 during the intervention period. Bold 
lines represent the control trial, where 3 g of placebo was administered each day. Dashed lines 
represent the cinnamon trial, where 3 g of cinnamon spice was administered each day until day 14, 
from when 3 g of placebo where given until the end of the 20 day intervention. The insert graph on 
each day represents total area under the insulin curve for each OGTT. Insulin AUC was decreased at 
day 14 in the cinnamon intervention compared to control. * represents significant differences at 
P<0.05. Data represents mean ± S.E.M. 
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Figure 6.5 – Area under the serum insulin response curve to OGTT on each study day 
OGTTs were undertaken at days 0, 1, 14, 16, 18, and 20. CONTROL (white bars) represents 3 g 
of placebo administered each day. CINNAMON (shaded bars) represents 3 g of cinnamon 
administered each day until day 14. Analysis of area under the insulin curve following OGTT revealed 
an intervention*day interaction (P<0.05). Further analysis indicated that measures at day 14 in the 
cinnamon trial were significantly lower than baseline (* indicates P<0.05) and all other days (P<0.05), 
and also that the AUC data at day 14 in the cinnamon trial was significantly lower than in the control 
trial (# indicates P<0.05). Data represents mean ± S.E.M. 
6.4.3 Changes in insulin sensitivity 
  
Figure 6.6 illustrates insulin sensitivity data derived from ISIOGTTMatsuda. Analysis showed a 
day*intervention interaction (P<0.05). Further examination revealed that the ISI at day 14 was 
significantly greater than at day 0 in the cinnamon trial (P<0.05), and that measures on day 14 of the 
cinnamon trial were greater than all days in control trial (P<0.05). 
 
Figure 6.6 – Changes in insulin sensitivity during each intervention period. 
OGTTs were undertaken at days 0, 1, 14, 16, 18, and 20. The trials follow the same legend as 
previous figures. The ISIOGTT index derived from Matsuda et al (1999) [219] revealed a 
day*intervention interaction (P<0.05) where insulin sensitivity at day 14 was increased compared to 
day 0 in the cinnamon trial (* indicates P<0.05), as well as being significantly greater than all days in 
the control trial (# indicates P<0.05). Data represents mean ± S.E.M. 
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6.5 Discussion 
 
Following a 3 g.day-1 supplementation for 14 days, insulin responses to OGTT were reduced (-
27%), and insulin sensitivity was improved in inactive but otherwise healthy individuals. However, 
these data do not show any persistent effects of long term cinnamon supplementation on insulin 
sensitivity following removal of the cinnamon stimulus. This study also confirms our findings from 
the previous chapter that an acute bolus of cinnamon spice can reduce glucose responses to OGTT 
performed 12 hours later (-13%). Although comparisons should be treated with caution, because the 
two cinnamon chapters used different subjects, the similar drop in the glucose AUC data from 
ingesting 5 g and 3 g of cinnamon the night before (-10% and -13%, respectively) may suggest that 
doses greater than 3 g do not provide greater benefit. 
 
This study was perhaps underpowered to detect significant interactions between time, day and 
trial in raw glucose and insulin concentrations following OGTT. Power calculations, with power set at 
0.8 and alpha at 0.05, reveal that based on the effect size in this study, investigating twenty subjects 
should be sufficient to detect statistically significant changes in a future experiment. This suggests 
that, with more subjects, significant differences in glucose responses at day 14 may arise, and 
therefore a more powerful study design may increase the potential value of cinnamon as a therapeutic. 
Nevertheless significant reductions in insulin AUC data and improvements in insulin sensitivity were 
detected after 14 days of cinnamon supplementation; illustrating that prolonged cinnamon 
supplementation may be useful for improving insulin sensitivity. However, these findings should not 
be directly extrapolated to obese/T2DM populations as the data was obtained using healthy 
individuals. Despite this our volunteers, although lean (BMI = 24 kg.m-2), did undertake less than the 
recommended physical activity guidelines [365]. Inactivity is a cardiovascular disease risk factor [200] 
and a key factor in determining progression along the insulin sensitivity continuum [192,366,367].   
 
The literature investigating long term cinnamon supplementation indicates increased glucose 
utilisation and increased activity of insulin signalling intermediates in mice [246] and rats [244], 
reversal of fructose-induced insulin resistance in rats [243], and improved fasting glycaemia and lipids 
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in humans [238,239]. A recent placebo-controlled study by Vanschoonbeek et al (2006) showed no 
effect of a 1.5 g.day-1 cinnamon intervention in postmenopausal T2DM patients [240]. This had a 
superior study design to the studies of Khan et al (2003) and Mang et al (2006) with strict 
pharmaceutical, dietary and exercise restrictions, but used only female subjects, and a relatively low 
dose, which might possibly account for the null finding [240]. Our data indicates improved insulin 
sensitivity in a healthy cohort but with no changes in fasting glycaemia. Mang et al (2006) 
demonstrated that large improvements in FPG are only likely in cases of very poor glycaemic control 
[239]. Our subjects’ fasting glycaemia was normal, and therefore improvements would be unlikely. 
The presence of a persistent effect of cinnamon on glycaemic control seen in Khan’s data is useful 
with regards to cost-benefit analysis, and patient compliance, such that constantly ongoing 
supplementation is not necessary, and failure to take a dose does not reverse all previous benefits. 
However, this current study fails to show any persistent effects on insulin sensitivity after stopping 
cinnamon supplementation. Furthermore, the OGTT glucose AUC data suggests that the effects of 
cinnamon wear off with continuous supplementation. Insulin AUC data however, was decreased by 
the accumulative effects of 14 days cinnamon feeding, yet these effects were quickly lost within 2 
days of ceasing cinnamon intake. It appears that the effects on postprandial glucose responses are 
rapid, whereas there is a delayed effect on insulin responses and insulin sensitivity. These mechanisms 
warrant further attention by investigating glucose uptake at the cellular level, intracellular insulin 
signalling cascades and transcriptional and translational regulation of genes and proteins involved in 
glucose metabolism. Imparl-Radosevich et al (1998) showed increased insulin receptor 
autophosphorylation and reduced glycogen synthase kinase-3β (GSK-3β) activity with cinnamon in 
adipocytes [241], and Qin et al (2005) has shown cinnamon-induced increases in skeletal muscle IRS-
1 tyrosine phosphorylation and PI3K association in rats [244]. Another study by Qin et al (2004) 
demonstrated that endothelial nitric oxide synthase (eNOS) inhibition prevents the effects of cinnamon 
in insulin resistant rats [243], suggesting a mechanism involving nitric oxide (NO), a compound 
implicated in insulin resistance [368]. Cinnamon may activate similar mechanisms in humans, but 
further work is required. 
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These findings indicate that in a lean but sedentary male population, long term cinnamon 
supplementation can improve insulin sensitivity but that the effects are rapidly reversed in the post-
intervention period. Despite the strong in vitro and in vivo animal evidence, the rather conflicting 
human findings confuse the therapeutic value of cinnamon, particularly when compared to the known 
impact of pharmaceutical, dietary and exercise interventions on insulin sensitivity and diabetes 
prognosis [191]. However, the increasing prevalence of obesity and diabetes suggests alternative 
therapeutic avenues should be explored. Further investigation of the long term effects of cinnamon on 
insulin sensitivity and intramuscular insulin signalling pathways in humans is required. 
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7. The effects of feeding frequency on insulin and ghrelin 
responses 
__________________________________________________ 
 
Co-authors: Edward Chambers, Asker E. Jeukendrup, Andrew A. Toogood, Andrew K. Blannin 
 
Publication status: under review in the Journal of Clinical Endocrinology and Metabolism 
 
 
7.1 Abstract 
 
Ghrelin, a nutrient-responsive gastrointestinal hormone, has been suggested to 
be involved in satiety regulation, adipogenesis and fuel oxidation rates. Recent work 
by Sugino et al (2002) demonstrates reduced postprandial ghrelin suppression with 
increased meal frequency in sheep, but no other variables were measured, nor is 
similar work available in humans. In this study five healthy male volunteers (aged 
24 ± 2 years, body mass 75.7 ± 3.2 kg, and BMI 23.8 ± 0.8 kg.m-2; mean ± S.E.M.) 
underwent three 8 hour feeding regimes: fasting (FAST), low-frequency (two meals) 
ingestion (LOFREQMEAL), and high-frequency (twelve meals) ingestion 
(HIFREQMEAL). Meals were equicaloric within trials, and total energy intake was 
equal between feeding trials. Meals consisted of 64% carbohydrate, 23% fat and 
13% protein. Total area under the curve for insulin and ghrelin responses did not 
differ between trials (one-way ANOVA, P>0.05). However, the negative 
relationship between increases in serum insulin and decreases in plasma ghrelin 
demonstrated during the FAST and LOFREQMEAL trials (P<0.05) was not seen 
during HIFREQMEAL (time-series analysis, P>0.05). This is the first study to 
investigate feeding frequency on insulin and ghrelin responses and their 
relationships in humans.  
 71
7.2 Introduction 
The recent escalating obesity trend in humans is due to an imbalance between energy intake and 
energy expenditure [1,2]. Energy intake is influenced by the effect of food’s energy density, total 
caloric content and feeding frequency and the extent to which these alter satiety. Of these factors, 
feeding frequency has received least attention. Human epidemiological evidence indicates increasing 
trends in recent years of dietary snacking and increased meal frequency [267,268], and such studies 
show positive relationships between snacking and increased energy intake and BMI [268], illustrating 
the potential importance of investigating feeding frequency. 
Several gastrointestinal peptides are involved in metabolic processes, and are dysregulated in 
states of metabolic disease [323,369,370]. One of these peptides, ghrelin, an orexigenic hormone 
released by the stomach prior to feeding, has also been implicated in the control of fuel metabolism, 
appetite, and pancreatic insulin release, factors quite central to the onset of metabolic disease [247]. In 
2002, Sugino et al reported the effects of meal frequency on ghrelin responses in sheep, investigating 
2 meals versus 4 meals versus ad libitum feeding [282]. It appeared that increased meal frequency 
resulted in decreased ghrelin responses during the course of the day [282]. However energy intake was 
not controlled between the different feeding regimes, with 200% of daily energy requirements being 
ingested in the ad libitum trial compared with 120% in the other trials, thus complicating the 
interpretation of their findings [282].  
Various eu- and hyperglycaemic clamp studies in humans demonstrate that postprandial ghrelin 
suppression appears to be dependent on insulin release [256,258,371], and in insulin-withdrawn type 1 
diabetics, postprandial ghrelin suppression is not apparent [256]. In insulin resistant states, such as 
obesity and T2DM where fasting ghrelin is downregulated [260], the magnitude of the postprandial 
ghrelin suppression is also smaller [372]. This is surprising given the hyperinsulinaemia that prevails 
in such states, and suggests that insulin sensitivity may be important to ghrelin responses. Sugino et al 
(2002) did not report insulin concentrations, and the effects of feeding frequency on concomitant 
insulin and ghrelin responses are not currently known. Therefore, this study investigated the effects of 
meal frequency during equicaloric feeding regimes upon the responses of insulin and ghrelin.  
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7.3 Method and materials 
Following ethical approval from The School of Sport and Exercise Sciences Safety and Ethics 
Subcommittee, five active but otherwise untrained male volunteers, aged 24 ± 2 years, body mass 75.7 
± 3.2 kg, with BMI 23.8 ± 0.8 kg.m-2 (mean ± S.E.M.), were recruited from the local community. All 
volunteers were assessed by a general health questionnaire and provided informed written consent 
prior to commencing the study. Participants had to make a total of three visits to the laboratory each 
separated by at least five days. A dietary record was taken for the day preceding the first test, and 
volunteers were instructed to refrain from consuming alcohol, caffeine, and from any exercise for 
twenty-four hours prior to each trial. The dietary record was for the purposes of diet replication before 
each trial. Participants were studied in a reclined position for the duration of all trials (though habitual 
activity for toilet visits was permitted), and each completed three 8 hour dietary interventions in a 
randomised cross-over design: a fasting control trial (FAST), a low-frequency meal trial 
(LOFREQMEAL), and a high-frequency meal trial (HIFREQMEAL). The meals provided in the trials had 
a macronutrient composition intended to replicate typical foods eaten during the day: 64% 
carbohydrate (1.93 g.kg-1.LOFREQMEAL-1, 0.32 g.kg-1.HIFREQMEAL-1), 23% fat (0.30 g.kg-
1.LOFREQMEAL-1, 0.05 g.kg-1.HIFREQMEAL-1), and 13% protein (0.42 g.kg-1.LOFREQMEAL-1, 0.07 g.kg-
1.HIFREQMEAL-1), and provided approximately 66% of the daily recommended intake (1667 kcal of 
recommended 2500 kcal for a 70 kg man) [48], the final 33% being an evening meal of the volunteers 
choice after completion of each trial. Trial meals consisted of white bread, Nutrigrain bars, apples, and 
cheddar cheese. The total energy intake was identical in each trial; however the number of meals was 
varied as explained below. 
 
7.3.1 FAST 
Volunteers arrived in the laboratory at 0800 hours following a 12 hour overnight fast, an 
intravenous cannula (BD Venflon, Oxford, UK) was inserted into an antecubital vein and a fasting 
blood sample was taken. Venous blood samples (3 ml) were drawn from the intravenous line every 
10 min until t = 8 hours to be later analysed for insulin and ghrelin concentrations. (See General 
Methods section for details of blood sample collection, storage and analysis). During the trial the 
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cannula was kept patent with 3 ml flushes of 0.9% NaCl(aq) isotonic saline (Baxter Healthcare, 
Northampton, UK) following each blood-letting. Each participant was given 14.3 ml.kg-1 body mass 
of water to consume ad libitum throughout the trial. This volume of water corresponded to 1 litre per 
70 kg of body mass, which was considered appropriate for the intervention. At the end of the trial the 
cannula was removed and the individual was sent home and instructed to return to the laboratory in 5-
7 days, fasted, having followed their dietary intake record.  
 
7.3.2 LOFREQMEAL 
 
The experimental protocol for this trial was identical to the FAST trial, except at t = 0 and 4 
hours, participants consumed a 4.95 g.kg-1 body mass mixed meal (composition described above). 
Subjects were given 15 min to ingest each meal. As well as the controlled intake of food, subjects 
were again asked to consume 14.3 ml.kg-1 body mass of water ad libitum throughout the trial.  
 
7.3.3 HIFREQMEAL 
This trial was identical to the FAST and to LOFREQMEAL trials except that 0.825 g.kg-1 body 
mass mixed meals were administered every 40 mins throughout the trial commencing at t = 0 mins, 
making a total of twelve meals. Participants were given 5 min to finish their meals. Again, the same 
volume of water was provided for ingestion ad libitum. 
 
In the feeding frequency literature there is no consistency in the number or composition of 
meals administered. The only available one-day intervention by Bertelsen et al (1993) used an 8 hour 
period, so that was replicated here [269]. The choice of 2 and 12 meals was made in relation to the 
range of meal frequencies in the available publications [269-275]: 1 to 3 (low-frequency) versus 6 to 
17 (high-frequency). 
 
7.3.4 Statistical Analysis 
Data are expressed as mean ± S.E.M. and significant differences were accepted at P<0.05. Raw 
insulin and ghrelin data were tested for normality and analysed by two-way (trial*time) repeated 
measures ANOVA. Main effects were analysed using Bonferroni post hoc tests. Raw insulin and 
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ghrelin data were converted to area under the curve (AUC) values by the trapezoidal method and trials 
were compared using one-way ANOVA. These analyses were carried out with SPSS for Windows 
12.0.1 (SPSS Inc, Chicago, US). Due to the influence of feeding on preprandial ghrelin concentrations 
documented in previous publications, i.e. preprandial rises and postprandial falls in plasma ghrelin 
concentration in proportion to caloric intake [250,251,373], in this study fasting ghrelin concentrations 
in each trial were also compared using one-way ANOVA to assess the effect the presentation of 
different sized meals in LOFREQMEAL and HIFREQMEAL may be having.  
In order to analyse the ghrelin response patterns in each of the three trials, and highlight the 
differences otherwise not detected by ANOVA, a pulse analysis was performed using Cluster 8, a sub-
program of Pulse_XP software (Pulse_XP, Virginia, US), to identify peaks and nadirs in the ghrelin 
data, as described by Veldhuis et al (1986) [374]. Cluster 8 is a statistically-based peak detection 
algorithm which locates significant increases and decreases (clusters) of hormone concentrations 
within a data series and has been used in several hundred endocrine publications. Cluster 8 does not 
assess hormone-hormone interaction but determines whether the data series of a single hormone 
represents pulsatile secretion rather than assay noise. This analysis then provides information about the 
pulse characteristics: number of peaks, number of nadirs, peak duration, area under the peak, etc, so 
that one can study changes in pulse characteristics under different conditions [374]. Such analysis is 
carried out using pooled t-testing on the experimental replicates. A peak is defined as a significant 
increase in concentration followed by a significant decrease (P<0.05). A nadir is defined as a 
significant decrease followed by a significant increase (P<0.05). Pulse analysis and peak detection is 
an important phenomenon in endocrine systems as it is thought that endocrine glands signal to their 
target tissues via episodic hormonal secretion [374-376]. Pulse_XP has been used in several hundred 
publications to investigate endocrine pulsatility. Pulse analysis of the insulin data was not possible due 
to the irregular sampling frequency (see Figure 7.1), upon which the software cannot work. 
 
In order to examine the relationships between insulin and ghrelin responses, a time-series 
analysis was applied to the data similar to that described by Box et al (1970) and Carroll (1977) 
[377,378]. For each subject, Pearson correlation coefficients (r) were calculated between insulin and 
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ghrelin concentrations synchronised in time. Each subject’s r value was converted to a z-score (a 
statistical normality score), the mean z-score for all subjects was calculated, this mean z-score was 
converted back to an r value (the mean correlation coefficient for all subjects), and the statistical 
significance (P) for the correlation was read from critical values tables. These calculations were 
performed in each of the three trials. Such analysis was carried out because previous publications have 
shown that changes in insulin concentrations appear to regulate changes in ghrelin concentrations 
[254-258,371]. In addition, to investigate any possible time delay between such relationships, the same 
calculations were made for correlations between insulin values and the ghrelin values measured 10, 
20, 30, 40, 50, 60, and 70 mins later. This was carried out because Cummings et al (2001) showed that 
the postprandial fall in ghrelin appears to be delayed after the rise in insulin [250]. Furthermore, in 
other examples of endocrine system synergy (e.g. ghrelin and growth hormone [379]) there is often a 
time-delay between such responses. The 70 min period was chosen in retrospect as, by examining the 
ghrelin/insulin profiles, a 70 min delay captured the largest postprandial changes in insulin and 
ghrelin. Note that due to the irregular sampling of insulin (see Figure 7.1), the correlations between 
insulin and ghrelin were performed between 15 data points only, at t = 0, 20, 40, 60, 80, 120, 180, 240, 
260, 280, 300, 320, 360, 420, and 480 min. This reduces the power of this analysis compared to a 
more frequent insulin sampling rate where more data points would be available to investigate these 
correlations. 
7.4 Results 
7.4.1 Serum insulin responses  
Figure 7.1 shows serum insulin responses during the three trials. Two-way ANOVA revealed a 
main effect of time (P<0.01), trial (P<0.01) and a time*trial interaction (P<0.01). Peak insulin 
concentrations of the two meals in LOFREQMEAL were different from one another (83.0 ± 7.6 versus 
57.1 ± 7.3 µU.ml-1; P<0.05). During the HIFREQMEAL trial serum insulin concentrations reached a 
plateau (mean concentration, 33.9 ± 7.7 µU.ml-1) during the 8 hour intervention period. During the 
FAST trial insulin steadily decreased over time from 15.6 ± 6.5 to 12.7 ± 6.9 µU.ml-1 (P>0.05). 
Responses were similar in all subjects. 
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Figure 7.1 – Serum insulin responses to mixed meal ingestion.  
The three trials, FAST, HIFREQMEAL, and LOFREQMEAL, represent 8 hour intervention periods 
where no meals, 12 meals, or 2 meals were ingested, respectively. Meals within trials were 
equicaloric, and total caloric consumption between HI- and LOFREQMEAL trials was identical. Data 
differed from baseline (t = 0 mins) at many time points: all except t = 20 mins in HIFREQMEAL; and all 
except t = 180, 240, 260, and 480 mins in LOFREQMEAL (# or * indicates P<0.05; ## indicates 
P<0.01). No differences were found during FAST (P>0.05). A main effect of trial and further post hoc 
analysis indicated that LOFREQMEAL and HIFREQMEAL were significantly different to FAST (P<0.05) 
but not to one another (P=0.13). Data represents mean ± S.E.M.   
 
 
 
Total area under the insulin response curves for the 8 hour periods were increased in 
LOFREQMEAL and HIFREQMEAL trials by 172 ± 37% and 142 ± 18% respectively when compared with 
FAST (P<0.05), but no differences were found between the two meal trials (P=0.18, Figure 7.2). 
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Figure 7.2 – Area under the serum insulin response curves following meal ingestion. 
The three trials depicted on the x-axis are described in brief in Figure 7.1. Total insulin 
responses (AUC) for the 8 hour period were greater in HIFREQMEAL and LOFREQMEAL than in FAST 
(* indicates P<0.05) but not different from one another (P=0.18). Data represents mean ± S.E.M.  
 
 
 
7.4.2 Plasma ghrelin responses 
Figure 7.3 illustrates the plasma ghrelin concentrations during each intervention. Analysis 
revealed a main effect of time (P<0.01), trial (P<0.01) and a time*trial interaction (P<0.01). 
Postprandial ghrelin nadirs between the two meals in LOFREQMEAL were not different (205 ± 10 
versus 200 ± 9 pmol.l-1; P>0.05). During FAST ghrelin steadily increased with time from 253 ± 9 to 
315 ± 9 pmol.l-1, reaching significance at several time points (P<0.05) (see Figure 7.3). No differences 
were found between fasting preprandial ghrelin concentrations (P>0.05), although the comparison 
between fasting ghrelin in LOFREQMEAL and HIFREQMEAL trials approached statistical significance 
(P=0.08). Responses were similar in all subjects. The three trials are represented as separate graphs in 
Figure 7.3 to aid clarity. 
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Figure 7.3 – Plasma ghrelin responses to mixed-meal ingestion  
The three trials, FAST, HIFREQMEAL, and LOFREQMEAL, represent 8 hour intervention periods 
where no meals, 12 meals, or 2 meals were ingested, respectively, as indicated by bold arrows. Data 
differed from baseline (t = 0 mins) at many time points in FAST and LOFREQMEAL (* indicates 
P<0.05; ** indicates P<0.01), no change from baseline was found in HIFREQMEAL (P>0.05). A main 
effect of trial and further post hoc analysis revealed that LOFREQMEAL and HIFREQMEAL were 
different from FAST (P<0.01) but not different from one another (P>0.05). No differences were found 
between fasting (preprandial) ghrelin concentrations in each trial (P>0.05), however LOFREQMEAL 
versus HIFREQMEAL approached significance (P=0.08). Pulse analysis revealed different numbers of 
significant peaks and nadirs between trials, illustrating the difference in ghrelin secretion patterns 
during the different feeding interventions. The flat-line inserts are arbitrary representations of the 
significant peaks and nadirs during the trial. Data are expressed as mean ± S.E.M.  
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Compared with FAST, total area under the ghrelin response curves for the 8 hour intervention 
periods were decreased by 19.4 ± 6.4% and 20.2 ± 4.5% during LOFREQMEAL and HIFREQMEAL trials 
respectively (P<0.05), but no differences were found between the two meal trials (P>0.05, Figure 7.4). 
 
Figure 7.4 – Area under the plasma ghrelin response curves following meal ingestion. 
The three trials depicted on the x-axis are described in brief in Figure 7.3. Total ghrelin 
responses for the 8 hour period were lower in HIFREQMEAL and LOFREQMEAL than FAST (* indicates 
P<0.05) but not different from one another (P>0.05). Data represents mean ± S.E.M.  
 
 
7.4.3 Ghrelin pulse analysis 
Figure 7.3 illustrates the significant peaks and nadirs from the pulse analysis (illustrated by the 
flat line inserts), showing that ghrelin exhibited four peaks and four nadirs during FAST, one peak and 
two nadirs during LOFREQMEAL and four peaks and five nadirs during HIFREQMEAL. Table 7.1 shows 
further information generated by the pulse analysis. 
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Table 7.1 – Ghrelin pulse analysis 
FAST, LOFREQMEAL, and HIFREQMEAL represent the same trials as described in Figure 7.3. 
Ghrelin responses between LOFREQMEAL and HIFREQMEAL were distinct as depicted by the different 
number of significant peaks and nadirs, and different peak and nadir characteristics. Matching 
superscript letters in each row represent statistically significant differences between trials (a, d and f 
represents P<0.001; b and e represents P<0.01; c and g represents P<0.05. These comparisons 
demonstrate significant differences in ghrelin pulsatility between the different feeding trials. Data 
represents mean ± S.E.M. 
 
 
7.4.4 Insulin-ghrelin interactions 
Figure 7.5 indicates the temporal relationship between the two hormones during the three trials 
as depicted by a time-series analysis. In the FAST trial there was a negative correlation between 
insulin and ghrelin concentrations (P<0.05). During LOFREQMEAL, there was no direct correlation 
(simultaneous insulin and ghrelin values, see insulin leads ghrelin by 0 mins on Figure 7.5) between 
insulin and ghrelin, however there was a negative correlation when insulin led ghrelin responses by 
20, 40 and 50 mins (P<0.05). During HIFREQMEAL no significant relationship existed between insulin 
and ghrelin responses (all time delays P>0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Ghrelin pulse characteristics FAST LOFREQMEAL HIFREQMEAL
  Number of peaks 4 1 4
  Peak width (min) 70.0 ± 66.8 e 230 a e 55.0 ± 38.7 a
  Peak height (pmol/l) 311 ± 3.51 d f 285 a d 247 ± 7.13 a f
  Peak area (pmol/l.min) 1455 ± 2169 e 8331 a e 496 ± 420 a
  Number of nadirs 4 2 5
  Nadir width (min) 5.00 ± 17.3 e g 45.0 ± 35.3 c e 20.0 ± 7.0 c g
  Nadir level (pmol/l) 287 ± 1.86 d f 199 ± 18.5 b d 226 ± 7.0 b f
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Figure 7.5 – Relationships between insulin and ghrelin responses.  
The three charts represent the time-series analysis in each trial. Correlation coefficients were 
calculated for relationships between insulin and ghrelin responses over the 8 hour period. These were 
calculated when the two variables were synchronised in time (insulin correlated with simultaneous 
ghrelin value, see “insulin leads ghrelin by 0 mins”), and relationships were also assessed between the 
insulin concentrations and the ghrelin concentrations observed 10, 20, 30, 40, 50, 60, and 70 mins 
later. The insert graph on each chart illustrates the trends in ghrelin (bold line, pmol.l-1) and insulin 
(dotted line, µU.ml-1) concentrations in the corresponding trial. During FAST there was a negative 
relationship between insulin and ghrelin (* represents P<0.05). During LOFREQMEAL there was a 
negative correlation between insulin and ghrelin responses, reaching significance when insulin led 
ghrelin by 20, 40 and 50 mins (* indicates P<0.05). During HIFREQMEAL there were no significant 
associations between insulin and ghrelin (P>0.05). 
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7.5 Discussion 
 
This data demonstrates that whilst the insulin and ghrelin responses to different feeding 
frequency regimes are quite different (Figures 7.1, 7.3, Table 7.1), such feeding patterns have no effect 
on the total (AUC) day long responses when caloric load is controlled (Figures 7.2 and 7.4). During a 
period of prolonged fasting, it was clear that insulin and ghrelin concentrations have an inverse 
relationship (Figure 7.5 FAST). This study also illustrates that during a period of low-frequency meal 
ingestion serum insulin concentrations are inversely related to plasma ghrelin concentrations (Figure 
7.5 LOFREQMEAL), but that when the same total caloric load is consumed in smaller individual meals 
across the day, this insulin-ghrelin relationship is not observed (Figure 7.5 HIFREQMEAL). 
 
The time-series analysis of the two hormones was carried out to investigate the effects of meal 
frequency on the insulin-ghrelin association reported in the literature; nutrient-induced rises in insulin 
may be required for postprandial ghrelin suppression [256,258,371]. Besides direct correlations, 
correlations with time delays of up to 70 mins between insulin and ghrelin values were also analysed 
to determine whether changes in insulin induce a delayed response in ghrelin. During a period of 
fasting, our data shows that insulin falls slightly and ghrelin rises slightly with time, causing an inverse 
correlation between the two variables (Figure 7.5, FAST). During a period of low-frequency feeding 
(2 meals in 8 hours), the results illustrate that although there is an insulin-ghrelin relationship, there is 
a delay (of approximately 20 minutes) between responses of the two hormones (Figure 7.5, 
LOFREQMEAL). No significant correlation exists when no time-delay between the hormone 
concentrations is applied (i.e. correlation of insulin with simultaneous ghrelin values, see insulin leads 
ghrelin by 0 mins, LOFREQMEAL on Figure 7.5). This illustrates that nutrient-induced rises in insulin 
may cause postprandial ghrelin suppression with a 20 min delay. Finally, during a period of high-
frequency meal ingestion (12 meals in 8 hours), either the hormone-hormone interaction is lost or 
insulin does not fluctuate sufficiently to influence ghrelin. However, during FAST where changes in 
insulin concentrations are small (Figure 7.1) there is a significant relationship between the two 
hormones (Figure 7.5), illustrating that only small changes in insulin are required for effects on 
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ghrelin, thus it is more likely that high-frequency meal ingestion actually reduces the insulin-ghrelin 
interaction. Whilst these are novel findings, these analyses are only correlations from which exact 
causality cannot be determined, and, due to the irregular insulin sampling frequency, the loss of power 
associated with fewer time points being analysed means that such interpretations must be made with 
caution and may indeed explain the loss of significant hormonal relationships in HIFREQMEAL. An 
improved study design would be to sample insulin and ghrelin regularly and frequently at identical 
intervals. Despite this, several studies have documented that insulin is required for postprandial 
ghrelin suppression [254-259,371]. Additionally, Anderwald et al (2003) showed reduced insulin-
stimulated ghrelin suppression in T2DM patients, illustrating the importance of insulin in regulating 
ghrelin [259]. The exact importance of an insulin-ghrelin relationship is unclear, but with insulin’s 
known involvement in metabolic flux and ghrelin’s implications with orexigenic neuropeptide 
networks [380], mitochondrial lipid metabolism gene expression [262] and fuel substrate selection 
[265], such a relationship may provide a useful avenue for metabolic research. Our findings indicate 
that high-frequency feeding may be detrimental to insulin’s control of ghrelin responses, a problem 
seen in T2DM patients [259]. However with only correlation analyses to make this interpretation, 
suggesting that increased feeding frequency contributes to metabolic disease would be purely 
speculative and further work would be required to explore this concept. 
 
The expense of ghrelin measurement limited this study to n = 5, however Sugino et al (2002) 
used the same subject number to show that increased feeding frequency decreased total ghrelin (AUC) 
responses [282]. The findings here show no differences in day-long AUC insulin or ghrelin responses, 
yet with only five subjects, the analysis was perhaps underpowered. Based on the effect size calculated 
in this study, a power calculation, with power set at 0.8 and alpha at 0.05, indicated that eight subjects 
should be sufficient to achieve statistically significant differences between trials in a future study. 
Several comparisons between the HIFREQMEAL and LOFREQMEAL trials approached significance and 
therefore a further study with a larger cohort may detect an effect. This would be interesting in that 
increased meal frequency may indeed reduce day-long insulin responses when energy intake is 
controlled. By examining the baseline data on Figure 7.3, it is also evident that some difference may 
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exist between fasting ghrelin concentrations prior to meal ingestion. The comparison between 
HIFREQMEAL and LOFREQMEAL again approached significance (P=0.08) and therefore with a larger 
sample size, it may be that a larger caloric load presented to an individual may cause a larger 
preprandial ghrelin surge. Preprandial ghrelin surges, triggered by visual or olfactory stimuli, are 
likely to provide a meal initiation signal that activate orexigenic neuropeptide pathways in the 
hypothalamus [52,381]. There is evidence illustrating calorie-dependent postprandial ghrelin 
suppression [251], but a calorie-dependent effect on the preprandial ghrelin surge would be a novel 
finding. In retrospect, more preprandial measures in the hour before feeding would have allowed 
greater insight into preprandial ghrelin changes. 
The exact importance of the postprandial ghrelin decline is unknown, but again it may be 
involved in satiety regulation. Recent work implicating ghrelin with adipogenesis and metabolic flux 
[262,264,265], suggests that this peptide, like insulin, may also be involved with postprandial nutrient 
storage and oxidation. Changes in typical ghrelin responses in the postprandial period may therefore 
disrupt such systems. Although this study shows that total ghrelin responses (AUC) are not altered by 
feeding frequency, the pulse analysis (Figure 7.3, flat-line, and Table 7.1) reveals clear differences in 
the ghrelin response pattern between trials, and so further research in this area is required to establish 
the importance of such changes in ghrelin secretion. A loss of insulin-regulated ghrelin fluctuations 
due to high-frequency feeding may affect ghrelin’s control of satiety and metabolic flux, yet this is 
speculative, and further work is required. Additionally, the data in Table 7.1 confirms findings from 
Koutkia et al (2004) [382] that showed pulsatile ghrelin responses during a fasting period with similar 
peak characteristics to those found here, yet pulsatility during feeding periods has not been reported in 
humans before and so our data adds new information to this limited evidence base. 
 
The meals used in this study were of mixed composition (64% carbohydrate, 23% fat and 13% 
protein) within the WHO macronutrient intake ranges [383], and were provided in equicaloric amounts 
during the two feeding interventions, controlling total energy intake. In a free living environment, data 
suggests that snacking is correlated to increased energy intake, and that snacks are generally high 
sugar or high fat foods [277,384,385]. Our meals derived 13% of total calories from free sugars, and 
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23% from fats, perhaps not representative of a usual snack. However, the definition of “snack” also 
causes problems for such investigations. Is a snack a smaller portion of a typical meal taken more 
frequently throughout the day, or does a snack represent a high-sugar/high-fat food taken between 
meals in addition to typical meals [386,387]? The two definitions could change both the research 
design and the subsequent results. Here a snack was chosen to represent a smaller-sized portion of a 
meal that was eaten more frequently throughout the day. In this approach we were able to isolate the 
effect of feeding frequency from the combination of factors involved in a free living situation such as 
feeding frequency and energy density of the snacks consumed. If high-sugar or high-fat snacks were 
eaten in addition to usual meals resulting in a hypercaloric energy intake it is probable that increased 
insulin and decreased ghrelin trends would be seen. This is however, speculative, and further work is 
needed to answer that question. 
 
These data were recorded from lean healthy volunteers, so care must be taken in predicting the 
outcome in a patient group. The current literature is mixed with regards to the efficacy of increased 
feeding frequency (or snacking) regimes in causing or treating metabolic anomalies. A number of 
studies report a positive impact of increased meal frequency on factors such as lipaemia, 
thermogenesis, and fasting glycaemia [269,275,276], whilst other studies show the opposite [271,277-
279], and further data show that no differences exist [272,280,281]. The observation in this study that 
increased feeding frequency may disrupt the insulin-ghrelin relationship may be relevant to diminished 
regulation of ghrelin seen in insulin resistance (discussed earlier). This is relevant to the increased 
snacking habits seen in our society [267,268], however these suggestions require further investigation. 
This study provides the only such data in humans, and therefore further work is prudent, particularly 
regarding the long-term effect of meal frequency. Also, given the inconclusive evidence in the 
literature regarding feeding frequency and its metabolic implications, large randomised controlled 
trials are required to resolve speculation that the current increases in snacking habits contribute to the 
epidemic increases in the frequency of obesity and T2DM.  
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8. The effect of time-delay between exercise and high-fat meal 
ingestion on postprandial lipaemia 
__________________________________________________ 
 
Co-authors: Andrew K. Blannin 
 
 
8.1 Abstract 
 
Postprandial lipaemia in humans is a useful marker of cardiovascular disease 
risk. It is well documented that low- to moderate-intensity exercise reduces 
postprandial lipaemia; however it is not fully understood how long this effect may 
persist. In this study eight healthy volunteers, aged 21 ± 1 years, body mass 72.3 ± 
2.3 kg, and BMI 23.0 ± 0.7 kg.m-2 (mean ± S.E.M.) undertook three 90 minute bouts 
of moderate intensity exercise (walking at 55% heart rate reserve) either 12, 24, or 
48 hours prior to a 6 hour oral fat tolerance test (OFTT; 71 kJ.kg-1; macronutrient 
composition 1.22 g.kg-1 fat, 1.21 g.kg-1 carbohydrate, and 0.20 g.kg-1 protein). Total 
triglyceride responses (AUC) to OFTT were attenuated by 24.6 ± 5.6% in the 12 
hour trial (P<0.01) and 19.9 ± 7.7% in the 24 hour trial (P<0.05) compared with the 
48 hour trial. Peak triglyceride concentrations were also reduced following the 12 
hour trial compared with the 48 trial (1113 ± 97.5 vs. 1526 ± 126 µmol.l-1 P<0.01), 
yet no differences were seen in fasting triglyceride measures (P>0.05). These 
findings suggest that a moderate-intensity exercise stimulus carried out 12 or 24 
hours ahead of a high fat meal exerts a larger effect on postprandial lipaemia than 
when carried out 48 hours before. These findings may be attributed to the delayed 
and transient exercise-induced increase in lipoprotein lipase activity or exposure 
(due to increased capillary perfusion), or due to suppression of hepatic very low 
density lipoprotein production. 
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8.2 Introduction 
 
Postprandial lipaemia is a useful marker of cardiovascular disease (CVD) risk [388]. Prolonged 
presence of triglyceride-rich lipoproteins in the circulation increases the opportunity for lipid exchange 
with cholesterol-rich lipoproteins, leading to events that promote atherogenesis such as a depletion of 
high density lipoprotein cholesterol and a decrease in the size of low density lipoproteins [285,389]. 
Besides this, the presence of triglycerides in the circulation activates inflammatory mechanisms in the 
endothelium, causing low-grade chronic inflammation, as indicated by increased levels of acute-phase 
proteins (e.g. CRP, fibrinogen, and PAI-1) which are also associated with elevated atherosclerotic risk 
[160]. Thus, circulating triglycerides may contribute to the vascular atherosclerotic process if levels 
are persistently elevated. In addition, as described in Chapter 1, elevated intracellular fatty acid 
derivatives, which ultimately are derived from circulating triglycerides, can contribute to inflammation 
and impede the insulin signal causing insulin resistance [100-103,163,164]. 
 
A single aerobic exercise bout can attenuate postprandial lipaemia in sedentary [308] and 
physically active [390] populations. It is also well documented that endurance-trained individuals 
exhibit decreased plasma triglyceride concentrations in both fasted and postprandial states [391], 
partly as a result of increased skeletal muscle triglyceride uptake via enhanced activity of heparin-
releasable lipoprotein lipase (LPL), the rate limiting enzyme in triglyceride clearance [392,393]. 
Endurance athletes also possess a large, well vascularised muscle mass and this may increase the 
availability of endothelial binding sites, in addition to the amount of LPL [391]. Thus, exercise can be 
a useful tool to reduce postprandial lipaemia. 
 
The effects of continuous versus intermittent exercise, exercise intensity and long-term training 
regimes upon triglyceride responses to high-fat meal ingestion are well documented [312,394-396]. 
The time course of lipaemic benefits following an exercise stimulus has also been investigated. Zhang 
et al (1998) demonstrated a marked improvement with exercise carried out 12 h prior to a fat meal 
compared with 1 h before [308], and Hardman et al (1998) have shown that the benefit on postprandial 
lipaemia remains until 60 h post-exercise [397]. The data of Zhang et al (1998) and Hardman et al 
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(1998) suggest the optimal time delay is longer than 1 h, but shorter than 60 h. Furthermore, one of the 
key mechanisms, increased LPL activity, begins to increase 4 h post-exercise [398,399] and is still 
elevated 24 h following the stimulus [392]. Hence, it is clear that exercise-induced improvements in 
postprandial lipaemia are delayed and transient. In addition, a period of de-training in athletes reduces 
LPL activity [400], and physical inactivity has been shown to suppress LPL activity compared to 
active controls [401]. The exact time course of the transient lipaemia-suppressing effects is unknown. 
This information would be useful when writing physical activity guidelines, particularly regarding the 
aspect of frequency. Therefore, the aim of this study was to investigate the time course of the 
beneficial effect by comparing the effect of a prolonged exercise bout carried out 12-, 24- or 48 h prior 
to a high fat meal. Although not available at the time of commencing this study, a publication by 
Zhang et al (2004) recently demonstrated reduced lipaemia following a 12 h but not a 24 h delay 
between prolonged moderate-intensity exercise and a high fat meal in obese hypertriglyceridaemic 
patients, suggesting that the beneficial effects are lost in the 12-24 h post-exercise period [402]. The 
current study presents similar data but in a lean, healthy cohort. 
 
8.3 Method and materials 
Following ethical approval from The School of Sport and Exercise Sciences Safety and Ethics 
Subcommittee, eight lean healthy volunteers, aged 21 ± 1 years, body mass 72.3 ± 2.3 kg, and BMI 
23.0 ± 0.7 kg.m-2 (mean ± S.E.M.), were recruited from the local community. All volunteers were 
assessed by a general health questionnaire and provided informed written consent prior to 
commencing the study. Each subject completed three interventions in a randomised cross-over design, 
each involving ingestion of a high fat meal (OFTT) that followed a moderate-intensity exercise bout 
carried out either 12, 24, or 48 h previously. Each exercise bout consisted of a 90 min treadmill walk 
at 55% of heart rate reserve (55% age-predicted HRR), recorded using a Polar A3 Heart Rate Monitor 
(Polar Electro, Kempele, Finland). Treadmill speed was maintained at 4 mph whilst gradient was set to 
attain the desired HRR. Exercise duration and intensity was chosen to replicate protocols from 
previous publications [403,404]. A dietary record was taken for two days preceding the first test for 
the purpose of diet replication prior to each subsequent trial, and subjects were instructed to refrain 
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from consuming alcohol, caffeine, and from any exercise regime for forty-eight hours prior to each 
trial. The test meals matched those of previous literature assessing exercise-induced postprandial 
lipaemia to allow comparison with such data [312,403]: 71 kJ.kg-1 body mass with a macronutrient 
composition of 1.22 g.kg-1 fat (66% of calories), 1.21 g.kg-1 carbohydrate (29% of calories) and 0.20 
g.kg-1 protein (5% of calories), consisting of whipping cream, ice cream, raisins, walnuts, and 
digestive biscuits. 
8.3.1 Exercise 48 hours before oral fat tolerance test (48 h trial) 
Subjects arrived in the laboratory at 0800 hours and completed a 90 min treadmill walk as 
described above. Following the exercise bout subjects were instructed to return to the laboratory 48 
hours later, again at 0800 hours, following an overnight fast. An intravenous cannula (BD Venflon, 
Oxford, UK) was inserted into an antecubital vein and a fasting blood sample was taken. The high-fat 
test meal (OFTT) was then administered at t = 0 h and further 5 ml venous blood samples were drawn 
from the intravenous line at t = ½, 1, 2, 4 and 6 h. During the trial the cannula was kept patent with 5 
ml flushes of 0.9% NaCl (aq) isotonic saline (Baxter Healthcare, Northampton, UK) following each 
blood sample. Plasma was stored at -70 ºC and triglyceride and glycerol concentrations were measured 
as described in the General Methods. Water was consumed ad libitum throughout. At the end of the 
trial the cannula was removed and the subject was sent home and instructed to return to the laboratory 
in 5-7 days, having followed their dietary intake record. A 48 h delay between exercise and OFTT was 
used as a control because in previous studies OFTTs in control (no exercise) trials were administered 
following 48 h abstinence from exercise, thus assuming the loss of exercise effects at this time point 
[307,312,405]. In addition, Aldred et al (1995) demonstrated no improvement in postprandial lipaemia 
following a 48 h delay between a 12 week exercise training regime and OFTT [307]. In this study an 
exercise trial 48 h prior to OFTT was used as a control so that factors such as time invested, contact 
with investigators and calories expended were equal between trials. 
 
8.3.2 Exercise 24 hours before oral fat tolerance test (24 h trial) 
The experimental set-up for this trial was identical to the 48 h trial. However, instead of a 48 h 
preprandial exercise bout, the 90 min walk was undertaken 24 h prior to the OFTT at 0800 hours. 
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Again, water was permitted ad libitum, and blood collection, storage and analysis followed the same 
practise. 
8.3.3 Exercise 12 hours before oral fat tolerance test (12 h trial) 
The experimental set-up was again identical to other trials, except the 90 min walk was 
undertaken 12 h prior to the OFTT, at 2000 hours, the night prior to the test meal. Water was again 
permitted ad libitum, and blood collection, storage and analysis followed the same practise. 
 
The time delays between exercise and OFTT (24 and 12 h) were chosen because the available 
literature at the time of commencing this study indicated that exercise-induced improvements in 
postprandial lipaemia or LPL activity are evident from 8- to 24 h post-exercise [392,406,407], but are 
lost beyond delays of 2 days or more [308,397]. 
 
8.3.4 Statistical Analysis 
Data are expressed as mean ± S.E.M. and statistical analysis was carried out using SPSS for 
Windows 12.0.1 (SPSS Inc, Chicago, US). Prior to statistical analysis triglyceride data was corrected 
for free glycerol (see General Methods for details). Triglyceride data was tested for normality and 
analysed using two-way (time*trial) repeated measures ANOVA. Main effects were analysed using 
Bonferroni post hoc tests. Raw triglyceride data was converted to area under the curve values by the 
trapezoidal method and trials were compared using one-way ANOVA followed by Bonferroni post 
hoc tests. Fasting (t = 0 min), peak (t = 120 min), and final (t = 360 min) triglyceride measures were 
also compared by one-way ANOVA, again followed by Bonferroni post hoc tests. Significant 
differences were accepted at P<0.05.  
 
8.4 Results 
 
8.4.1 Heart rate data during exercise trials 
Average heart rates during the final hour (steady state) of each trial were 136 ± 2, 136 ± 2, and 
138 ± 3 beats per minute (~55% HRR) for the 12, 24 and 48 h trials, respectively. These values were 
not significantly different between trials (P>0.05). 
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8.4.2 Plasma triglyceride responses to high-fat meal ingestion 
Figures 8.1 and 8.2 show plasma triglyceride responses to OFTT during the three trials. Plasma 
triglyceride responses were significantly decreased in the 12 h and 24 h trials by 24.6 ± 5.6% (P<0.01) 
and 19.9 ± 7.7% (P<0.05) respectively when compared with the 48 h trial, but no differences were 
found between the 12 h and 24 h trials (P>0.05). No significant differences were found in fasting 
plasma triglyceride measures taken before the OFTTs: 605 ± 35, 595 ± 47, and 669 ± 119 µmol.l-1 for 
the 12, 24 and 48 hour trials, respectively (P>0.05). Peak (t = 120 mins) triglyceride concentration was 
significantly lower in the 12 h trial compared with the 48 h trial (P<0.01), but no differences were 
found at t = 360 mins (P>0.05). 
 
Figure 8.1 – Plasma triglyceride responses following meal ingestion. 
The three trials, 12 h trial, 24 h trial, and 48 h trial, represent a 90 min moderate-intensity 
exercise bout carried out 12, 24, or 48 h prior to a high fat meal. Triglyceride concentrations at t = 60, 
120, 240, and 360 mins were significantly different from baseline in all trials (** indicates P<0.01). 
Triglyceride responses in the 12 h trial were lower compared with the 48 h trial (P<0.05) but not the 
24 h trial (P=0.08). The 48 h trial was not different to the 24 h trial (P>0.05). No differences were 
found in fasting or t = 360 min triglyceride measures between trials (P>0.05), however peak 
triglyceride concentrations (t = 120 mins) were lower in the 24 h trial compared to the 48 h trial 
(P<0.01). Data represents mean ± S.E.M. 
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Figure 8.2 – Area under the plasma triglyceride response curve during meal ingestion 
The 12 h trial, 24 h trial, and 48 h trial, once again represent a 90 min moderate-intensity 
exercise bout carried out 12, 24, or 48 h prior to a high fat meal. Triglyceride responses in the 12 h 
trial and the 24 h trial were significantly lower than in the 48 h trial (** indicates P<0.01; * indicates 
P<0.05) though not different from one another (P>0.05). Data represents mean ± S.E.M. 
 
8.5 Discussion 
 
This study demonstrates that in lean healthy individuals the effects of a prolonged moderate-
intensity exercise bout upon postprandial lipaemia are altered by the time course between the exercise 
stimulus and meal ingestion. A time delay of 12 and 24 h between a 90 min moderate-intensity walk 
and OFTT had a beneficial effect (25% and 20%, respectively) on circulating postprandial 
triglycerides when compared to a delay of 48 h, yet no effects on fasting plasma triglyceride 
concentrations were seen. In contrast to the findings of Zhang et al (2004), who employed a similar 
study design in obese hypertriglyceridaemic patients [402], this study demonstrates that the lipaemic 
benefits are still present 24 hours after a single exercise bout in a lean healthy population. In 
concordance with previous studies, these beneficial effects are gradually lost as the time delay 
between exercise and meal is increased. 
 
Triglyceride concentrations in the postprandial period are determined by chylomicron 
appearance from the gut, hepatic VLDL-TG output, and peripheral tissue triglyceride hydrolysis by 
LPL [389]. Although these factors were not measured in this study it is worth speculating about the 
mechanisms in an attempt to interpret the current findings. Meal ingestion stimulates pancreatic 
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insulin release which downregulates muscle LPL activity and upregulates adipose LPL activity 
[398,408-411]. Endothelial LPL provides the rate limiting step for triglyceride hydrolysis and 
clearance from the systemic circulation, and an exercise stimulus has been shown to increase skeletal 
muscle LPL activity in a delayed and transient manner [399,412]. Evidence suggests that skeletal 
muscle LPL activity is elevated at up to 24 h post-exercise [304], possibly explaining the effects of 
exercise carried out 12- and 24- compared with 48 h prior to OFTT in this study. During exercise, 
Kiens et al (1998) showed that, intramuscular triglyceride (IMTG) stores are reduced, and in the post-
exercise recovery period, increased skeletal muscle LPL activity may serve to replenish these stores 
[413]. In addition, both meal ingestion and exercise can increase muscle tissue capillary perfusion thus 
allowing increased delivery of substrates to the LPL on the capillary endothelium [414]. However, no 
data is available to show the effect of exercise on insulin-enhanced capillary perfusion when there is a 
delay of many hours between the exercise and the meal. Further studies are required to establish if 
prior exercise causes a greater insulin action on capillary perfusion. Finally, exercise has been shown 
to reduce serum VLDL-TG concentrations [415] and hepatic output [416], and increase ketone levels 
[417], indicative of increased hepatic fat oxidation. However, there is no direct evidence of exercise-
induced suppression of hepatic VLDL-TG output in humans. Furthermore, no studies have 
investigated the time course of this exercise-induced change in hepatic contribution. 
 
Zhang et al (2004) studied the effects of a similar protocol in obese middle-aged 
hypertriglyceridaemic and impaired glucose tolerant male subjects, and found attenuated postprandial 
lipaemia 12 h following a 60 min moderate-intensity exercise bout when compared with a 24 h delay 
[402]. In contrast, our data indicates no significant difference between 12- and 24 h delays between 
exercise and OFTT. This may be explained by the increased duration of exercise used during our 
trials, and thus increased energy expenditure, possibly prolonging the effects of our stimulus upon 
postprandial lipaemia.  
 
The use of a 48 h delay was used as the control trial in this study for reasons explained in the 
Methods and Materials above (section 8.3.1). It is possible that in our study a 48 h delay between 
exercise and meal may still be having an effect on postprandial lipaemia, however given the current 
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evidence that exercise-induced increased LPL activity is apparent 24 h after but not 48 h after exercise 
[304,406], and that the literature shows no effects of exercise on triglyceride levels 2 days post-
stimulus [307,397,405], it is unlikely that a “no exercise” trial would differ from our OFTT48hpre trial. 
However, the lack of a “no exercise” control trial is a design weakness of this study, as previous 
literature used different subjects and therefore extrapolations cannot be accurately drawn. A further 
limitation of this study may be the lack of oxygen consumption (VO2) data. Whilst stating VO2 is 
typical of exercise studies, it has been clearly demonstrated that exercise duration and intensity is not 
an important determinant of postprandial lipaemia if energy expenditure is consistent [289]. Our 
subjects exercised at 55% HRR, levels comparable with heart rates observed in previous studies. 
These levels were maintained in each trial, thus energy expenditure would be equal between trials. 
 
Assuming that 48 h after exercise there is a minimal effect on postprandial lipaemia, this study 
demonstrates that a 90 min moderate-intensity walk carried out 12- or 24 h prior to a high fat meal 
improves postprandial lipaemia, a marker of CVD risk, in lean healthy individuals. Given the 
significant loss of the beneficial effect between 24 and 48 hours after exercise this work suggests 
physical activity should be performed daily in order to maintain optimal lipaemic control. 
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9. General Discussion 
___________________________________________________________________________ 
 
9.1 General Findings 
 
The following five paragraphs summarise the novel findings that this thesis adds to the current 
literature. 
9.1.1 Reliability of the OGTT 
Chapter 3 demonstrated that some OGTT-derived measures of insulin sensitivity (ISIOGTT) are 
reliable when pre-test diet and exercise is standardised. It was concluded that ISIOGTTMatsuda was the 
most reliable measure, and together with previous observations that this variable is a valid estimate of 
insulin sensitivity measured against the clamp, ISIOGTTMatsuda was considered the most appropriate 
measure to investigate insulin sensitivity during repeated measures experiments.  
 
9.1.2 The use of stable isotope tracers in OGTT protocols 
Dual tracer methodology was applied to the OGTT technique in Chapter 4, allowing the 
determination of glucose rate of appearance into the systemic circulation from exogenous (meal) and 
endogenous (hepatic) sources during the standard 2 hour 75 g OGTT. Use of this technique in a patient 
group may allow monitoring of treatment (pharmaceutical or lifestyle) interventions upon hepatic 
insulin sensitivity. 
 
9.1.3 Cinnamon ingestion and insulin sensitivity 
The work in Chapter 5 showed that acute cinnamon ingestion (a single 5 g bolus) improved 
insulin sensitivity by up to 13%, with a persistent effect lasting 12 hours. Chronic cinnamon feeding (3 
g.day-1 for 14 days) was also shown to improve insulin sensitivity in Chapter 6, though these effects 
were not accumulative or persistent in the 6 day period following removal of the cinnamon feeding 
stimulus. Given the relatively small improvements seen in these studies, and the mixed evidence in the 
literature as to the effect of cinnamon in humans in vivo [238-240], further work is required before 
cinnamon may be considered a therapeutic supplement for states of insulin resistance. 
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9.1.4 Feeding frequency, serum insulin and plasma ghrelin responses 
The findings in Chapter 7 supported evidence that insulin may regulate postprandial ghrelin 
responses. Also, this hormone-hormone interaction appeared to have a time delay of approximately 20 
minutes. Feeding frequency had no effect on total day-long (AUC) insulin or ghrelin responses, yet it 
was demonstrated that the insulin-ghrelin relationship seen during low-frequency (2 meals.day-1) 
feeding was less apparent when the same total caloric load was ingested in twelve equicaloric meals 
(high frequency feeding). Eating frequency may, therefore, affect insulin’s control of ghrelin release.  
 
9.1.5 Exercise and postprandial lipaemia 
When compared to a 48-hour delay between moderate-intensity exercise and a high-fat meal, 
postprandial lipaemia was suppressed by up to 25% when the exercise bout was carried out 12 or 24 
hours prior to the meal. These data from Chapter 8 suggest that the beneficial effect of exercise on 
circulating triglycerides is lost beyond 24 hours post-stimulus in lean healthy subjects. This illustrates 
that daily exercise should be recommended in order to maintain optimal lipaemic control. 
 
9.2 Further investigation 
 
The recent rise in obesity and diabetes prevalence (General Introduction, Section 1.1) 
demonstrates the urgent need for effective therapies. The large diabetes intervention studies in the US, 
Finland, China and Japan [190,191,193,209] have generated convincing evidence that lifestyle 
alteration via diet and increased physical activity is a powerful therapeutic tool. However, this 
knowledge has not stopped the rise in metabolic disease (General Introduction, Section 1.1). 
Therefore, the communication of this knowledge to the public is either failing or compliance by the 
public to these known effective therapies is poor. The information from such intervention studies is 
available in both scientific and lay publications, however, the health benefits of lifestyle alteration are 
not directly taught in the UK school education system, and therefore such information has to be 
actively sought. In addition, the Department of Health’s statistics show that the recommended levels of 
physical activity are only achieved by 29% of the population in the UK [39,40], demonstrating that, in 
addition to poor education, compliance to the known effective therapeutic methods is also poor. In 
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order to tackle this problem, current education must be improved, or researchers must search for 
alternative therapeutic methods to which compliance may be easier. This PhD project added new 
information to recent alternative research directions investigating symptoms of the metabolic 
syndrome. Whilst patient or “at risk” cohorts were not used, statistical differences were achieved in 
lean, healthy, yet minimally active volunteers, and therefore it would be prudent to continue such 
investigations in patient groups.  
 
In Chapter 3, ISIOGTT measures were demonstrated to be reliable. Reliability of these measures 
has not been investigated in insulin resistant individuals, nor have several of these ISI indices been 
validated against the gold standard glycaemic clamp methodology across a range of insulin sensitive 
states and therefore this remains an avenue for future work. Chapter 4 described the use of dual tracer 
methodology during the standard 2 h 75 g OGTT in lean healthy individuals. Adaptation of this tool 
into a patient population would also be sensible. If it were demonstrated that the hepatic contribution 
to the rate of glucose appearance was increased in obese individuals, then this would provide a good 
basis for the use of this new tool in monitoring treatment regimes targeted at improving hepatic insulin 
sensitivity. Chapters 5 and 6 provide evidence for the positive effects of cinnamon ingestion on 
glycaemic control and insulin sensitivity. In animal and cell lines, several research groups have 
elucidated some of the mechanisms at play [235-237,241-246], however, very little is known 
regarding the effects of cinnamon ingestion in humans at the molecular and cellular level. With the use 
of mass spectrometry it may be possible to measure the active component of cinnamon (e.g. MHCP or 
cinnamaldehyde [236,356]) in the blood, to calculate its rate of appearance and half life. However, 
whilst some data concerning cinnamon’s active component is available, describing a phenolic lipid-
soluble compound [236,356], its cellular targets or kinetics are not fully understood. Further work may 
also focus on cinnamon’s regulation of the insulin signalling cascade in human skeletal muscle, as has 
been demonstrated in rats and mice by Kim et al (2006) and Qin et al (2003, 2004) [243-246]. Chapter 
7 further investigated recent findings that insulin may be responsible for postprandial ghrelin 
suppression. The correlation analyses performed here cannot determine causality, but do concur with 
existing evidence that changes in insulin are likely to affect ghrelin responses [254-259]. The exact 
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physiological significance of an insulin-ghrelin association is not yet known, however the two 
hormones are nutrient-responsive and involved in regulating energy balance, and therefore further 
work studying such factors would be wise. Feeding frequency is a factor that receives little attention in 
comparison to meal composition and caloric intake [266]. The available literature shows mixed 
evidence regarding its effects on factors surrounding metabolic disease [269-281], thus large-scale 
randomised controlled studies are required [266]. Some in vitro evidence suggests that prolonged 
hyperinsulinaemia may have detrimental effects on the liver, increasing VLDL-TG output, a factor 
associated with the metabolic syndrome [418,419]. Prolonged periods of high-frequency feeding may 
result in a state of hyperinsulinaemia during the day, and therefore it would be interesting to 
investigate such effects in vivo in future work. Finally, Chapter 8 concluded that moderate-intensity 
exercise should be performed daily in order to maximise lipaemic benefits. With findings from Zhang 
et al (2004) [402] in obese subjects, the time course of exercise effects are now quite well established, 
however the mechanisms of exercise-induced triglyceride suppression are not fully understood. In 
humans, it is well documented that increased activity of LPL accounts for increased triglyceride 
clearance from the systemic circulation [304,398,399,412,420,421]. However, the evidence also 
suggests that LPL is not the sole factor involved in lowered triglyceride levels following exercise 
because basal triglyceride uptake is not altered by exercise despite reduced triglyceride concentrations 
[417], and LPL activity 18 hours post-exercise has been shown to be unaltered despite lowered 
postprandial lipaemia [422]. Whilst work in animal models has confirmed that exercise may reduce 
hepatic VLDL-TG production [416,423], only measures of plasma VLDL and 3-hydroxybutyrate 
concentrations have been made in such studies in humans [415,417]. It would therefore be useful to 
investigate the time course effects of exercise on the lipid partitioning between adipose tissue, liver 
and muscle to further understand the mechanisms involved.  
 
9.3 General conclusion 
 
Chapter 1 demonstrates the great impact that metabolic abnormalities associated with insulin 
resistance have on mortality, morbidity and global health care costs and economy. Despite a clear 
understanding of the lifestyle factors that lead to such conditions, and the interventions that can be 
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applied to relieve symptoms and reduce morbidity, Department of Health statistics clearly show that 
trends in obesity, diabetes and CVD continue to rise (Figures 1.1, 1.2, and 1.3; [2]). This PhD project 
identified and extended the investigation of some recent viewpoints surrounding metabolic 
abnormalities that may prompt alternative treatment strategies. Besides further validating the OGTT as 
a useful research tool, this thesis demonstrates that dietary supplementation with cinnamon, meal 
frequency, and exercise time course may be important factors to consider when prescribing nutritional 
and physical activity lifestyle alterations. 
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